var title_f33_26_34208="Estradiol: Drug information";
var content_f33_26_34208=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Estradiol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12624521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12624522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/25/14746?source=see_link\">",
"       Estradiol (systemic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/1/38935?source=see_link\">",
"       Estradiol (topical): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9422 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.65.114.212-1237D62C13-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_26_34208=[""].join("\n");
var outline_f33_26_34208=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/25/14746?source=related_link\">",
"      Estradiol (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?38/1/38935?source=related_link\">",
"      Estradiol (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_26_34209="McDonald cerclage";
var content_f33_26_34209=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    McDonald cerclage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 431px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_26_34209=[""].join("\n");
var outline_f33_26_34209=null;
var title_f33_26_34210="Severe tricuspid regurgitation";
var content_f33_26_34210=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe tricuspid regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The four chamber view in a patient with severe tricuspid regurgitation (TR) shows right atrial (RA) enlargement (panel A); the RA, usually similar in size to the left atrium (LA), is larger and more spherical. With color flow Doppler imaging, the TR jet fills much of the RA (panel B); as the jet crosses the valve plane it is broad, suggesting a significant lesion. Panel C shows the continuous wave Doppler (CW) tracing from across the tricuspid valve (TV). The systolic portion of the tracing shows a dense waveform that is almost triangular in shape; this is in contrast to the parabolic waveform seen in milder degrees of TR. The sharp deceleration producing this characteristic waveform is known as the v-wave cut off sign, which is one of the most consistently reliable signs of TR severity. Also favoring a more severe lesion is the E point of the tricuspid inflow signal which reaches a velocity of over 1.3 meter/sec, a value that is twice the normal TV velocity Panel D is from a patient with mixed TR and tricuspid stenosis (TS); the v-wave cut-off suggests severe TR and the slow deceleration and high velocity of the inflow signal suggests an element of TS.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_26_34210=[""].join("\n");
var outline_f33_26_34210=null;
var title_f33_26_34211="Lumbosacral spinal lipoma";
var content_f33_26_34211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lumbosacral spinal lipoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 409px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal magnetic resonance imaging (MRI) study&nbsp;showing a lumbosacral spinal lipoma (asterisk) on FLAIR (A) and T2 (B) sequences. The latter view shows that the lipoma extends into the subcutaneous fat (arrowhead), and hence is palpable on physical exam in this patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Chaouki El-Khoury, BS, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_26_34211=[""].join("\n");
var outline_f33_26_34211=null;
var title_f33_26_34212="Pediculosis capitis nits";
var content_f33_26_34212=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pediculosis capitis nits",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pediculosis capitis. Note the whitish nits found along the hair shafts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Chung EK, Boom JA, Datto GA, Matz PS (Eds). Visual Diagnosis in Pediatrics. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Courtesy of Hans B Kersten, MD. Copyright &copy; 2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_26_34212=[""].join("\n");
var outline_f33_26_34212=null;
var title_f33_26_34213="Guaifenesin and codeine: Pediatric drug information";
var content_f33_26_34213=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Guaifenesin and codeine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?43/15/44277?source=see_link\">",
"    see \"Guaifenesin and codeine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/43/25268?source=see_link\">",
"    see \"Guaifenesin and codeine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14854544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Warns of Codeine Use in Children After Tonsillectomy and/or Adenoidectomy",
"     </span>",
"     <span class=\"collapsible-date\">",
"      August 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The FDA has issued a Drug Safety Communication after reviewing reports of children who developed serious adverse effects, including death, after receiving codeine in the usual dosage range for pain relief following tonsillectomy and/or adenoidectomy for obstructive sleep apnea syndrome. Three deaths occurred in children that had evidence of a genetic variation (&ldquo;ultrarapid metabolizers&rdquo;) which results in faster and more complete conversion of codeine to morphine, possibly leading to overdose or death. The estimated incidence of this genetic variation is ~1-7 per 100 people, but may be higher in some ethnic groups.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Healthcare professionals should be aware of the risks associated with the administration of codeine or codeine-containing drugs in children after tonsillectomy and/or adenoidectomy for obstructive sleep apnea and should use the lowest effective dose for the least amount of time on an as-needed basis. Parents and caregivers who observe signs of overdose in a child such as unusual sleepiness, confusion, or difficult or noisy breathing should stop codeine administration and seek medical attention immediately.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm313631.htm#\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm313631.htm#",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F177668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Allfen CD;",
"     </li>",
"     <li>",
"      Allfen CDX;",
"     </li>",
"     <li>",
"      Codar&reg; GF;",
"     </li>",
"     <li>",
"      Dex-Tuss;",
"     </li>",
"     <li>",
"      Guaiatussin AC;",
"     </li>",
"     <li>",
"      Iophen C-NR;",
"     </li>",
"     <li>",
"      M-Clear;",
"     </li>",
"     <li>",
"      M-Clear WC;",
"     </li>",
"     <li>",
"      Mar-Cof&reg; CG;",
"     </li>",
"     <li>",
"      Robafen AC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antitussive",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Cough Preparation",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Expectorant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?43/15/44277?source=see_link\">",
"      see \"Guaifenesin and codeine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;2 years, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-6 years: 1-1.5 mg/kg codeine/day divided into 4 doses administered every 4-6 hours (maximum dose: 30 mg/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-11 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Capsule: Guaifenesin 200 mg and codeine 9 mg: 1 capsule every 4 hours (maximum daily dose: 6 capsules/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Liquid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Guaifenesin 100 mg and codeine 6.33 mg per 5 mL: 7.5 mL every 4-6 hours (maximum daily dose: 45 mL/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Guaifenesin 100-200 mg and codeine 8-10 mg per 5 mL: 5 mL every 4 hours (maximum daily dose: 30 mL/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Guaifenesin 300 mg and codeine 10 mg per 5 mL: 2.5 mL every 4-6 hours (maximum daily dose: 20 mL/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet: Guaifenesin 400 mg and codeine 10-20 mg:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     tablet every 4-6 hours (maximum daily dose: 3 tablets/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule: Guaifenesin 200 mg and codeine 9 mg: 2 capsules every 4 hours (maximum daily dose: 12 capsules/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Liquid:",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:8em;text-align:justify;\">",
"     Guaifenesin 100 mg and codeine 6.33 mg per 5 mL: 15 mL every 4-6 hours (maximum daily dose: 90 mL/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:8em;text-align:justify;\">",
"     Guaifenesin 100-200 mg and codeine 8-10 mg per 5 mL: 10 mL every 4 hours (maximum daily dose: 60 mL/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:8em;text-align:justify;\">",
"     Guaifenesin 300 mg and codeine 10 mg per 5 mL: 5 mL every 4-6 hours (maximum daily dose: 40 mL/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet: Guaifenesin 400 mg and codeine 10-20 mg: 1 tablet every 4-6 hours (maximum daily dose: 6 tablets/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F177658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     M-Clear: Guaifenesin 200 mg and codeine phosphate 9 mg [contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Codar&reg; GF: Guaifenesin 200 mg and codeine phosphate 8 mg per 5 mL (473 mL) [contains propylene glycol; cotton candy flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dex-Tuss: Guaifenesin 300 mg and codeine phosphate 10 mg per 5 mL (473 mL) [ethanol free, gluten free, sugar free; contains propylene glycol; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Iophen C-NR: Guaifenesin 100 mg and codeine phosphate 10 mg per 5 mL (473 mL) [contains propylene glycol, sodium benzoate; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     M-Clear WC: Guaifenesin 100 mg and codeine phosphate 6.33 mg per 5 mL (473 mL) [contains propylene glycol; cotton candy flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: Guaifenesin 100 mg and codeine phosphate 10 mg per 5 mL (5 mL, 10 mL, 118 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mar-Cof&reg; CG: Guaifenesin 225 mg and codeine phosphate 7.5 mg per 5 mL (473 ml) [ethanol free, sugar free; contains propylene glycol, sodium benzoate, sodium 6 mg/5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral: Guaifenesin 100 mg and codeine phosphate 10 mg per 5 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Guaiatussin AC: Guaifenesin 100 mg and codeine phosphate 10 mg per 5 mL (118 mL, 473 mL)  [contains ethanol 3.5%, sodium 1 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robafen AC: Guaifenesin 100 mg and codeine phosphate 10 mg per 5 mL (120 mL, 480 mL) [contains ethanol 3.5%, sodium 4 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allfen CD: Guaifenesin 400 mg and codeine phosphate 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allfen CDX: Guaifenesin 400 mg and codeine phosphate 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F177644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Oral solution, syrup",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F177684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Capsule: C-V; Liquid products: C-V; Tablet: C-III",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with a large quantity of fluid to ensure proper action; may administer with food to decrease nausea and GI upset from codeine",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary control of cough due to minor throat and bronchial irritation",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F177686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to guaifenesin, codeine, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1059088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (morphine, hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone); discontinue immediately if symptoms of allergic or hypersensitivity reactions occur. Use with caution in patients with adrenal insufficiency (Addison&rsquo;s disease ); biliary tract impairment; CNS depression/coma; prostatic hyperplasia; urinary stricture; thyroid dysfunction; or severe liver, pulmonary, or renal insufficiency.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Not recommended for use for cough control in patients with a productive cough; not recommended as an antitussive for children &lt;2 years of age. Debilitated patients may be particularly susceptible to adverse effects of narcotics. Use caution when combining with other CNS depressants (eg, centrally acting antiemetics, general anesthetics, phenothiazines, sedative-hypnotics) as there may be additive CNS effects. If combined therapy is needed, consider reducing the dose of one or both agents.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with two or more copies of the variant CYP2D6*2 allele (ie, CYP2D6 \"ultra-rapid metabolizers\"); these patients may have extensive conversion of codeine to morphine with resultant increased opioid-mediated effects.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Some products contain phenylalanine which must be used with caution in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Codeine may cause CNS depression which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Respiratory depression may occur even at therapeutic dosages; use with extreme caution in patients with respiratory diseases including asthma, emphysema, COPD, cor pulmonale, hypoxia, hypercapnia, pre-existing respiratory depression, significantly decreased respiratory reserve, other obstructive pulmonary disease, kyphoscoliosis, or other skeletal disorder which may alter respiratory function. Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur. May cause hypotension; use with caution in patients with circulatory shock, hypovolemia, impaired myocardial function, or those receiving drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Codeine may obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Physical and psychological dependence may occur; abrupt discontinuation after prolonged use may result in withdrawal symptoms or seizures. Warn patients of possible impairment of alertness or physical coordination. Concurrent use of agonist/antagonist analgesics (ie, pentazocine, nalbuphine, and butorphanol) may precipitate withdrawal symptoms and/or reduce analgesic efficacy in patients following prolonged therapy with mu opioid agonists. Infants born to women physically dependent on opioids will also be physically dependent and may experience respiratory difficulties or opioid withdrawal symptoms (neonatal abstinence syndrome). Symptoms of opiate withdrawal may include excessive crying, diarrhea, fever, hyper-reflexia, irritability, tremors, or vomiting. High potential for abuse; healthcare providers should be alert to problems of abuse, misuse, and diversion.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Some products contain sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites; avoid use of sodium benzoate products in neonates. Some liquids contains propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use liquids containing propylene glycol with caution in neonates. Capsules contain tartrazine which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F177652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatostatin Analogs: May decrease the metabolism of Codeine. The formation of two major codeine metabolites (morphine and norcodeine) may be impaired by somatostatin analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3070371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1059094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/43/25268?source=see_link\">",
"      see \"Guaifenesin and codeine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increase fluid and fiber intake to avoid constipation. Avoid alcohol. Codeine may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. May be habit-forming; do not discontinue abruptly",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review),\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/26/34213/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13344 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-218.189.88.190-50AA3700D9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_26_34213=[""].join("\n");
var outline_f33_26_34213=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14854544\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177668\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059095\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059089\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177658\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177644\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177684\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059100\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059099\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177686\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059102\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059088\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059087\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299424\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177652\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3070371\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059086\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059094\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13344\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13344|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?43/15/44277?source=related_link\">",
"      Guaifenesin and codeine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/43/25268?source=related_link\">",
"      Guaifenesin and codeine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_26_34214="Amoxicillin and clavulanate potassium: Pediatric drug information";
var content_f33_26_34214=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amoxicillin and clavulanate potassium: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?42/56/43912?source=see_link\">",
"    see \"Amoxicillin and clavulanate potassium: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/33/5653?source=see_link\">",
"    see \"Amoxicillin and clavulanate potassium: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F134614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Amoclan;",
"     </li>",
"     <li>",
"      Augmentin ES-600&reg;;",
"     </li>",
"     <li>",
"      Augmentin XR&reg;;",
"     </li>",
"     <li>",
"      Augmentin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F134615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Amoxi-Clav;",
"     </li>",
"     <li>",
"      Apo-Amoxi-Clav&reg;;",
"     </li>",
"     <li>",
"      Clavulin&reg;;",
"     </li>",
"     <li>",
"      Novo-Clavamoxin;",
"     </li>",
"     <li>",
"      ratio-Aclavulanate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Beta-lactam and Beta-lactamase Combination",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Penicillin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11432525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Dosing based on amoxicillin component; dose and frequency are product specific; not all products are interchangeable, using a product with the incorrect amoxicillin:clavulanate ratio could result in subtherapeutic clavulanate concentrations or severe diarrhea: 30 mg (amoxicillin component)/kg/day divided every 12 hours using the 125 mg/5 mL suspension",
"     <b>",
"      only",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/56/43912?source=see_link\">",
"      see \"Amoxicillin and clavulanate potassium: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Dosing based on amoxicillin component; dose and frequency are product specific; not all products are interchangeable, using a product with the incorrect amoxicillin:clavulanate ratio could result in subtherapeutic clavulanic acid concentrations or severe diarrhea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants 1-3 months: 30 mg (amoxicillin component)/kg/day divided every 12 hours using the 125 mg/5 mL suspension",
"     <b>",
"      only",
"     </b>",
"     ; for infants &ge;2 months, 90 mg (amoxicillin component)/kg/day divided every 12 hours using the 600 mg/5 mL suspension",
"     <b>",
"      only",
"     </b>",
"     can be used for acute otitis media or sinusitis (severe, recurrent or treatment failure of previous antibiotic therapy) (AAP, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents 3 months to 16 years and &lt;40 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     General infection (use the higher end of the range for more severe infections): 20-40 mg (amoxicillin component)/kg/day in divided doses every 8 hours using the 125 mg/5 mL or 250 mg/5 mL suspension",
"     <b>",
"      only",
"     </b>",
"     ;",
"     <b>",
"      or",
"     </b>",
"     25-45 mg (amoxicillin component)/kg/day divided every 12 hours using the 200 mg/5 mL suspension, 400 mg/5 mL suspension, 200 mg chewable tablet, or 400 mg chewable tablet",
"     <b>",
"      only",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Acute otitis media or sinusitis (severe, recurrent or treatment failure of previous antibiotic therapy): 90 mg (amoxicillin component)/kg/day divided every 12 hours using the 600 mg/5 mL suspension",
"     <b>",
"      only",
"     </b>",
"     (AAP, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Community-acquired pneumonia: Beta-lactamase positive or nontypable",
"     <i>",
"      H. influenzae",
"     </i>",
"     strains: 80-100 (amoxicillin component) mg/kg/day in divided doses every 8 hours using the 600 mg/5 mL suspension",
"     <b>",
"      only",
"     </b>",
"     (Bradley, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;40 kg, Adolescents &ge;40 kg or &ge;16 years, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Less severe infection: 250 mg every 8 hours using the 250 mg tablet",
"     <b>",
"      only",
"     </b>",
"     ;",
"     <b>",
"      or",
"     </b>",
"     500 mg every 12 hours using the 500 mg tablet, 125 mg/5 mL suspension, or 250 mg/5 mL suspension",
"     <b>",
"      only",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     More severe infections and respiratory tract infections: 500 mg every 8 hours using the 500 mg tablet, 125 mg/5 mL suspension, or 250 mg/5 mL suspension",
"     <b>",
"      only",
"     </b>",
"     ;",
"     <b>",
"      or",
"     </b>",
"     875 mg every 12 hours using the 875 mg tablet, 200 mg/5 mL suspension, or 400 mg/5 mL suspension",
"     <b>",
"      only",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Acute bacterial sinusitis: 2000 mg every 12 hours for 10 days using the 1000 mg extended release tablet",
"     <b>",
"      only",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Bite wounds (animal/human), COPD, erysipelas, or pyelonephritis (acute, uncomplicated): 875 mg every 12 hours using the 875 mg tablet, 200 mg/5 mL suspension, or 400 mg/5 mL suspension",
"     <b>",
"      only",
"     </b>",
"     ;",
"     <b>",
"      or",
"     </b>",
"     500 mg every 8 hours using the 500 mg tablet, 125 mg/5 mL suspension, or 250 mg/5 mL suspension",
"     <b>",
"      only",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Diabetic foot: 2000 mg every 12 hours for 7-14 days using the 1000 mg extended release tablet",
"     <b>",
"      only",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Diverticulitis, perirectal abscess: 2000 mg every 12 hours for 7-10 days using the 1000 mg extended release tablet",
"     <b>",
"      only",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Febrile neutropenia: 875 mg every 12 hours using the 875 mg tablet, 200 mg/5 mL suspension, or 400 mg/5 mL suspension",
"     <b>",
"      only",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pneumonia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Aspiration: 875 mg every 12 hours using the 875 mg tablet, 200 mg/5 mL suspension, or 400 mg/5 mL suspension",
"     <b>",
"      only",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Community-acquired: 2000 mg every 12 hours for 7-10 days using the 1000 mg extended release tablet",
"     <b>",
"      only",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Skin abscess: 875 mg every 12 hours using the 875 mg tablet, 200 mg/5 mL suspension, or 400 mg/5 mL suspension",
"     <b>",
"      only",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing interval in renal impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Do not use 875 mg tablet or extended release tablets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute: 250-500 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: 250-500 every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Moderately dialyzable (20% to 50%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250-500 mg every 24 hours; administer dose during and after dialysis. Do not use extended release tablets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis: Moderately dialyzable (20% to 50%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amoxicillin: Administer 250 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clavulanic acid: Dose for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous arteriovenous or venovenous hemofiltration effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amoxicillin: ~50 mg of amoxicillin/L of filtrate is removed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clavulanic acid: Dose for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F134591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral: 200: Amoxicillin 200 mg and clavulanate potassium 28.5 mg per 5 mL (50 mL, 75 mL, 100 mL); 250: Amoxicillin 250 mg and clavulanate potassium 62.5 mg per 5 mL (75 mL, 100 mL, 150 mL); 400: Amoxicillin 400 mg and clavulanate potassium 57 mg per 5 mL (50 mL, 75 mL, 100 mL); 600: Amoxicillin 600 mg and clavulanate potassium 42.9 mg per 5 mL (75 mL, 125 mL, 200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Amoclan:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     200: Amoxicillin 200 mg and clavulanate potassium 28.5 mg per 5 mL (50 mL, 75 mL, 100 mL) [contains phenylalanine 7 mg/5 mL and potassium 0.14 mEq/5 mL; fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     400: Amoxicillin 400 mg and clavulanate potassium 57 mg per 5 mL (50 mL, 75 mL, 100 mL) [contains phenylalanine 7 mg/5 mL and potassium 0.29 mEq/5 mL; fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     600: Amoxicillin 600 mg and clavulanate potassium 42.9 mg per 5 mL (75 mL, 125 mL, 200 mL) [contains phenylalanine 7 mg/5 mL, potassium 0.248 mEq/5 mL; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Augmentin&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     125: Amoxicillin 125 mg and clavulanate potassium 31.25 mg per 5 mL (75 mL, 100 mL, 150 mL) [contains potassium 0.16 mEq/5 mL; banana flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     200: Amoxicillin 200 mg and clavulanate potassium 28.5 mg per 5 mL (50 mL, 75 mL, 100 mL) [contains phenylalanine 7 mg/5 mL and potassium 0.14 mEq/5 mL; orange flavor] [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     250: Amoxicillin 250 mg and clavulanate potassium 62.5 mg per 5 mL (75 mL, 100 mL, 150 mL) [contains potassium 0.32 mEq/5 mL; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     400: Amoxicillin 400 mg and clavulanate potassium 57 mg per 5 mL (50 mL, 75 mL, 100 mL) [contains phenylalanine 7 mg/5 mL and potassium 0.29 mEq/5 mL; orange flavor] [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Augmentin ES-600&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     600: Amoxicillin 600 mg and clavulanate potassium 42.9 mg per 5 mL (75 mL, 125 mL, 200 mL) [contains phenylalanine 7 mg/5 mL, potassium 0.23 mEq/5 mL; strawberry cream flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Tablet, oral: 250: Amoxicillin 250 mg and clavulanate potassium 125 mg; 500: Amoxicillin 500 mg and clavulanate potassium 125 mg; 875: Amoxicillin 875 mg and clavulanate potassium 125 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Augmentin&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     250: Amoxicillin 250 mg and clavulanate potassium 125 mg [contains potassium 0.63 mEq/tablet] [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     500: Amoxicillin 500 mg and clavulanate potassium 125 mg [contains potassium 0.63 mEq/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     875: Amoxicillin 875 mg and clavulanate potassium 125 mg [contains potassium 0.63 mEq/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Tablet, chewable, oral: 200: Amoxicillin 200 mg and clavulanate potassium 28.5 mg [contains phenylalanine]; 400: Amoxicillin 400 mg and clavulanate potassium 57 mg [contains phenylalanine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: Amoxicillin 1000 mg and clavulanate acid 62.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Augmentin XR&reg;: 1000: Amoxicillin 1000 mg and clavulanate acid 62.5 mg [contains potassium 12.6 mg (0.32 mEq) and sodium 29.3 mg (1.27 mEq) per tablet; packaged in either a 7-day or 10-day package]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F134575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Can be given without regard to meals. Administer at the start of a meal to decrease the frequency or severity of GI side effects; do not administer with a high fat meal (clavulanate absorption is decreased); may mix with milk, formula, or juice; shake suspension well before use",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reconstituted oral suspension should be refrigerated; discard unused suspension after 10 days; store tablets, chewable tablets, and powder for oral suspension at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infections caused by susceptible organisms involving the lower respiratory tract, otitis media, sinusitis, skin and skin structure, and urinary tract; spectrum same as amoxicillin in addition to beta-lactamase producing",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     ,",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      N. gonorrhoeae",
"     </i>",
"     , and",
"     <i>",
"      S. aureus",
"     </i>",
"     (not MRSA) (FDA approved in neonates, infants, children, adolescents, and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F134644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Augmentin&reg; may be confused with amoxicillin, Azulfidine&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F134641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Diaper rash, skin rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort, diarrhea, loose stools, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Vaginitis, vaginal mycosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Moniliasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Alkaline phosphatase increased, cholestatic jaundice, flatulence, headache, hepatic dysfunction, hepatitis, liver function tests increased, prothrombin time increased, thrombocytosis, vasculitis (hypersensitivity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Additional adverse reactions seen with",
"     <b>",
"      ampicillin-class antibiotics:",
"     </b>",
"     Agitation, agranulocytosis, alkaline phosphatase increased, anaphylaxis, anemia, angioedema, anxiety, behavioral changes, bilirubin increased, black &ldquo;hairy&rdquo; tongue, confusion, convulsions, crystalluria, dizziness, enterocolitis, eosinophilia, erythema multiforme, exanthematous pustulosis, exfoliative dermatitis, gastritis, glossitis, hematuria, hemolytic anemia, hemorrhagic colitis, indigestion, insomnia, hyperactivity, interstitial nephritis, leukopenia, mucocutaneous candidiasis, pruritus, pseudomembranous colitis, serum sickness-like reaction, Stevens-Johnson syndrome, stomatitis, transaminases increased, thrombocytopenia, thrombocytopenic purpura, tooth discoloration, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amoxicillin, clavulanic acid, penicillins, or any component; history of amoxicillin/clavulanic acid-associated cholestatic jaundice or hepatic dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with history of cephalosporin hypersensitivity; in patients with renal dysfunction, doses and/or frequency of administration should be modified in response to the degree of renal impairment. Some formulation may contain phenylalanine and must be avoided or used with caution in patients with phenylketonuria. May cause diarrhea; reported incidence (&le;14.5%)  is higher than with amoxicillin alone. Due to amoxicillin-clavulanic acid ratios, not all products are interchangeable; use of an inappropriate product for a specific dosage could result in either diarrhea (which may be severe) or subtherapeutic clavulanic acid concentrations leading to decreased clinical efficacy.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Epstein-Barr virus infection, acute lymphocytic leukemia or cytomegalovirus infection increase the risk for amoxicillin-induced maculopapular rash. Pseudomembranous colitis has been reported; prolonged use may result in superinfection. Serious hypersensitivity reactions, including anaphylaxis, have been reported.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F134584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May enhance the potential for allergic or hypersensitivity reactions to Amoxicillin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Penicillins may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F134587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F134602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Both amoxicillin and clavulanic acid cross the placenta. Maternal use of amoxicillin/clavulanate has generally not resulted in an increased risk of birth defects. A possible increased risk of necrotizing enterocolitis in neonates or bowel disorders in children exposed to amoxicillin/clavulanate",
"     <i>",
"      in utero",
"     </i>",
"     has been observed. In women with acute infections during pregnancy, amoxicillin/clavulanate may be given if an antibiotic is required and appropriate based on bacterial sensitivity; however, use is not recommended in the management of preterm premature rupture of membranes. Oral ampicillin-class antibiotics are poorly absorbed during labor. When used during pregnancy, pharmacokinetic changes have been observed with amoxicillin alone (refer to the Amoxicillin monograph for details).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1045067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     With prolonged therapy, monitor renal, hepatic, and hematologic function periodically",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clavulanic acid binds and inhibits beta-lactamases that inactivate amoxicillin resulting in amoxicillin having an expanded spectrum of activity; amoxicillin interferes with bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins and causing cell wall death",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1045074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Both amoxicillin and clavulanate are well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Both widely distributed into lungs, pleural, peritoneal, synovial, and ascitic fluid as well as bone, gynecologic tissue, and middle ear fluid; crosses the placenta; excreted in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amoxicillin: 17% to 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clavulanate: 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Clavulanic acid: Metabolized in the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life of both agents in adults with normal renal function: &sim;1 hour; amoxicillin pharmacokinetics are not affected by clavulanic acid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Amoxicillin: 60% to 80%; excreted unchanged in the urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: &sim;30% of amoxicillin removed by 3-hour hemodialysis; supplemental dose recommended after hemodialysis (do",
"     <b>",
"      not",
"     </b>",
"     use extended release tablets)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1045066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/33/5653?source=see_link\">",
"      see \"Amoxicillin and clavulanate potassium: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse GI effects may occur less frequently if taken with food. Report persistent diarrhea to physician.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1045076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Products may not be interchangeable. Both the 250 mg and 500 mg tablets contain the same amount of clavulanic acid; two 250 mg tablets are not equivalent to one 500 mg tablet. Additionally, four 250 mg tablets or two 500 mg tablets are not equivalent to a single 1000 mg extended release tablet. Based upon usual dosing in pediatric patients &lt;40 kg, typical &ldquo;TID&rdquo; regimens provide 5-10 mg/kg/day of clavulanate and &ldquo;BID&rdquo; regimens 3.4-6.4 mg/kg/day  .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Appearance of a rash should be carefully evaluated to differentiate a nonallergic amoxicillin rash from a hypersensitivity reaction. Amoxicillin rash occurs in 5% to 10% of children receiving amoxicillin and is a generalized dull, red, maculopapular rash, generally appearing 3-14 days after the start of therapy. It normally begins on the trunk and spreads over most of the body. It may be most intense at pressure areas, elbows, and knees. Incidence of amoxicillin rash is higher in patients with viral infections,",
"     <i>",
"      Salmonella",
"     </i>",
"     infections, lymphocytic leukemia, or patients with hyperuricemia who are receiving allopurinol.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media, \"Diagnosis and Management of Acute Otitis Media,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 113(5):1451-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/26/34214/abstract-text/15121972/pubmed\" id=\"15121972\" target=\"_blank\">",
"        15121972",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/26/34214/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, \"Management of Community-Acquired Pediatric Pneumonia in an Era of Increasing Antibiotic Resistance and Conjugate Vaccines,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2002, 21(6):592-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/26/34214/abstract-text/12182396/pubmed\" id=\"12182396\" target=\"_blank\">",
"        12182396",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gan VN, Kusmiesz H, Shelton S, et al, &ldquo;Comparative Evaluation of Loracarbef and Amoxicillin-Clavulanate for Acute Otitis Media,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1991, 35(5):967-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/26/34214/abstract-text/1854178/pubmed\" id=\"1854178\" target=\"_blank\">",
"        1854178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoberman A, Paradise JL, Burch DJ, et al, &ldquo;Equivalent Efficiency and Reduced Occurrence of Diarrhea From a New Formulation of Amoxicillin/Clavulanate Potassium (Augmentin&reg;) for Treatment of Acute Otitis Media in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1997, 16(5):463-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/26/34214/abstract-text/9154538/pubmed\" id=\"9154538\" target=\"_blank\">",
"        9154538",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reed MD, &ldquo;Clinical Pharmacokinetics of Amoxicillin and Clavulanate,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1996, 15(10):949-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/26/34214/abstract-text/8895939/pubmed\" id=\"8895939\" target=\"_blank\">",
"        8895939",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman ST, Bisno AL, Clegg HW, et al, \"Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/26/34214/abstract-text/22965026/pubmed\" id=\"22965026\" target=\"_blank\">",
"        22965026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thoene DE and Johnson CE, &ldquo;Pharmacotherapy of Otitis Media,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1991, 11(3):212-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/26/34214/abstract-text/1862012/pubmed\" id=\"1862012\" target=\"_blank\">",
"        1862012",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Todd PA and Benfield P, &ldquo;Amoxicillin/Clavulanic Acid. An Update of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Use,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1990, 39(2):264-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/26/34214/abstract-text/2184003/pubmed\" id=\"2184003\" target=\"_blank\">",
"        2184003",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12639 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-FD0A04FE88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_26_34214=[""].join("\n");
var outline_f33_26_34214=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134614\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134615\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045068\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11432525\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045060\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134591\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134575\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045072\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045064\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045071\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134644\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134641\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045075\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045059\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045058\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298742\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134584\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134587\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134602\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045067\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045057\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045074\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045066\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045076\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12639\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12639|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/56/43912?source=related_link\">",
"      Amoxicillin and clavulanate potassium: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/33/5653?source=related_link\">",
"      Amoxicillin and clavulanate potassium: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_26_34215="Failure to thrive in elderly adults: Evaluation";
var content_f33_26_34215=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Failure to thrive in elderly adults: Evaluation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/26/34215/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/26/34215/contributors\">",
"     Kathryn Agarwal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/26/34215/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/26/34215/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/26/34215/contributors\">",
"     J  Andrew Billings, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/26/34215/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/26/34215/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/26/34215/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Institute of Aging describes failure to thrive (FTT) as a \"syndrome of weight loss, decreased appetite and poor nutrition, and inactivity, often accompanied by dehydration, depressive symptoms, impaired immune function, and low cholesterol\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/1\">",
"     1",
"    </a>",
"    ]. Many of these features of FTT are actually defined as features of frailty including weight loss, malnutrition, and inactivity. In geriatric practice, FTT describes a syndrome of global decline that occurs in older adults as a worsening of physical frailty that is frequently compounded by cognitive impairment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    functional disability. FTT describes a point further along a geriatric functional continuum that is closer to full dependence and death, with &ldquo;frailty as a mid-point between independence and pre-death&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term FTT has long been used in pediatrics to describe infants who are unable to gain weight and have physical and cognitive developmental impairments and depressive symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/3\">",
"     3",
"    </a>",
"    ]. Pediatric patients with FTT have not achieved their expected functional level, while elders with FTT are unable to maintain their functional status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/1\">",
"     1",
"    </a>",
"    ]; the symptom complex is similar at both ends of the age spectrum.",
"   </p>",
"   <p>",
"    FTT describes the late stages of decline and may represent a final common pathway toward death. The goal in evaluation and management of FTT is to identify contributing factors that can be modified or reversed, such as assistance with meals to improve nutrition or treatment of infection that may lead to premature death, while keeping in mind the patient and family&rsquo;s goals and wishes. Some authors cite concerns that the terminology \"failure to thrive\" impedes appropriate patient evaluation and management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/1\">",
"     1",
"    </a>",
"    ], and its use has fallen out of favor. However, we find it a useful term to describe a clinical syndrome encompassing frailty, disability, and neuropsychiatric impairment.",
"   </p>",
"   <p>",
"    Due to the difficulty in precisely defining FTT as a syndrome in clinical practice, data are limited regarding its incidence, epidemiology, and outcomes. The individual components associated with FTT, however, are clearly predictive of mortality.",
"   </p>",
"   <p>",
"    This topic will discuss an overview of the evaluation of patients with suspected FTT. Management of older patients with FTT is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/29/42455?source=see_link\">",
"     \"Failure to thrive in elderly adults: Management\"",
"    </a>",
"    ), as are discussions cited below on individual components of FTT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COMPONENTS OF FTT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure to thrive (FTT) may be considered to result from interaction of three components:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Physical frailty",
"     </li>",
"     <li>",
"      Disability",
"     </li>",
"     <li>",
"      Impaired neuropsychiatric function",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Major contributors to decompensation are medication side effects, medical comorbidities, and psychosocial factors (",
"    <a class=\"graphic graphic_figure graphicRef82609 \" href=\"mobipreview.htm?36/14/37103\">",
"     figure 1",
"    </a>",
"    ). The key feature that must be present in FTT is frailty, which includes weight loss, malnutrition, and physical inactivity. The elements in this model are commonly seen in patients with FTT; however, all factors are not required to yield a state of functional and medical decline consistent with FTT. For example, an older patient with cancer, weight loss, frailty, and functional decline or disability may have FTT without any element of neuropsychiatric impairment. Another example may be a patient with advanced dementia with increasing disability, frailty, and weight loss due to consequences of the dementia process. In contrast, a patient with a chronic disability and dementia may not have FTT because he does not have physical frailty or weight loss and be at a stable functional level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Frailty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frailty, representing decreased physiologic reserve affecting multiple systems, is a vulnerable state for future adverse health outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/4\">",
"     4",
"    </a>",
"    ]. Frailty is most often identified when aging and disease lead to a critical mass of deficits, resulting in impaired physical function and malnutrition or weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28792?source=see_link&amp;anchor=H2#H2\">",
"     \"Frailty\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frailty phenotype is defined by meeting three or more of these five criteria derived from the Cardiovascular Health Study (CHS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/6\">",
"     6",
"    </a>",
"    ]. Some of these criteria, however, are not readily assessed in the non-research clinical setting.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weight loss (&ge;5 percent of body weight in last year)",
"     </li>",
"     <li>",
"      Exhaustion (positive response to questions regarding effort required for activity)",
"     </li>",
"     <li>",
"      Weakness (decreased grip strength)",
"     </li>",
"     <li>",
"      Slow walking speed (&gt;6 to 7 seconds to walk 15 feet)",
"     </li>",
"     <li>",
"      Decreased physical activity (Kcals spent per week: males expending &lt;383 Kcals and females &lt;270 Kcal)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A somewhat simpler index of frailty, from the Study of Osteoporotic Fractures (SOF), has been shown to predict the risk of falls, disability, fractures, and death as well as the CHS frailty phenotype in both women and men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The SOF index defines frailty as the presence of at least two of three criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Weight loss of 5 percent or more over two years",
"     </li>",
"     <li>",
"      Inability to stand from a chair five times without using arms to push up",
"     </li>",
"     <li>",
"      Negative response to the question \"Do you feel full of energy?\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of elders in nursing homes in the United States are believed to be frail [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/5\">",
"     5",
"    </a>",
"    ], although this does not suggest that the majority of nursing home residents have failure to thrive. One study showed that frailty is associated with subsequent disability and death, independent of comorbid diseases, health habits, and psychosocial characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;A well-accepted definition of clinically significant weight loss is 5 percent of body weight over a period of 6 to 12 months. Optimal body mass index (BMI) in the older adult is considered to be 24 to 29",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?39/41/40593?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/9\">",
"     9",
"    </a>",
"    ]. This is higher than generally considered optimal for younger adults.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a group of 983 community-dwelling older adults, those with a BMI between 25 and 29 had less functional decline compared to elders in the &ldquo;normal&rdquo; or lower BMI range of 18.5-24.9 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A BMI &lt;22",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      in community-based elders was associated with an increased one-year mortality risk and poorer functional status [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In men over 75 years of age, a BMI &lt;20.5 was associated with a 20 percent greater mortality rate; for the same age group in women, a BMI &lt;18.5 was associated with a 40 percent increase in mortality in a 14-year prospective study in the United States [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/12\">",
"       12",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unintentional weight loss is a significant predictor of death in nursing home patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/13\">",
"     13",
"    </a>",
"    ]. It has also been associated with decline in activities of daily living (ADLs), increased hospital complications, admissions to nursing homes, and poorer quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Unintentional weight loss has been shown to have a negative effect on functional decline regardless of baseline BMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Normal aging is associated with small amounts of weight loss per year, approximately 0.1 to 0.2 kg per year after age 70 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/9\">",
"     9",
"    </a>",
"    ]. This slow weight loss is associated with an increased ratio of fat to lean body mass. Physiologic changes with aging, such as decreased olfactory sensitivity, are felt to increase anorexia and promote weight loss.",
"   </p>",
"   <p>",
"    Although the frailty phenotype includes weight loss, obese elders may also be considered frail by meeting the other criteria for the frailty phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/15\">",
"     15",
"    </a>",
"    ]. Even if weight loss is not apparent, the patient should be evaluated for evidence of malnutrition.",
"   </p>",
"   <p>",
"    Causes of weight loss may broadly be divided into two categories: inadequate intake and increased energy expenditure. Many elders, especially those in nursing homes, lack adequate intake of calories and nutrients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis for the etiology of weight loss and malnutrition in elders is extensive and includes medical conditions, medications, and socioeconomic factors (",
"    <a class=\"graphic graphic_table graphicRef54156 \" href=\"mobipreview.htm?15/36/15948\">",
"     table 1",
"    </a>",
"    ). Poor oral health and dry mouth are risk factors for decreased oral intake due to changes in taste and difficulty with chewing and swallowing.",
"   </p>",
"   <p>",
"    Medications that are most commonly associated with weight loss in older adults are shown in a table (",
"    <a class=\"graphic graphic_table graphicRef68249 \" href=\"mobipreview.htm?23/37/24157\">",
"     table 2",
"    </a>",
"    ). The list of associated medical diagnoses is the same as for FTT, with malignancy the most common cause of involuntary weight loss and the most common medical diagnosis in case-series of patients admitted with FTT (",
"    <a class=\"graphic graphic_table graphicRef59323 \" href=\"mobipreview.htm?5/14/5357\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/17-20\">",
"     17-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Neuromuscular function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several physiologic changes with age affect neuromuscular function, including decreases in skeletal muscle mass and strength (sarcopenia), aerobic capacity, and forced expiratory volume. These changes reduce the physiologic reserve and increase vulnerability to stressors.",
"   </p>",
"   <p>",
"    A cycle of frailty has been described in which malnutrition associated with frailty adds to age-related loss of lean muscle mass or sarcopenia. This contributes to loss of strength, decreased aerobic capacity, decreased walking speed, and, ultimately, significant disability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vitamin D deficiency is common in both community-dwelling and institutionalized elders and has been associated with falls and gait imbalance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Additionally, low serum 25 (OH) vitamin D is associated with an increased risk for nursing home admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/4/22602?source=see_link\">",
"     \"Falls in older persons: Risk factors and patient evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Disability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disability is defined as difficulty or dependency in completing tasks essential for self-care and independent living. Screening for disability involves asking about activities of daily living (ADLs) and instrumental activities of daily living (IADLs).",
"   </p>",
"   <p>",
"    The Katz ADL scale assesses basic life skills: the patient's ability to bathe, dress, toilet themselves, transfer, feed themselves, and maintain continence (",
"    <a class=\"graphic graphic_table graphicRef66451 \" href=\"mobipreview.htm?2/13/2269\">",
"     table 4",
"    </a>",
"    ). The Lawton IADL scale is intended for use in community-dwelling elders to identify their current level of independent living skills and how those abilities change over time. It assesses activities required to live independently: using the telephone, shopping and using transportation, preparing meals, doing housework, and managing finances and medications (",
"    <a class=\"graphic graphic_table graphicRef63647 \" href=\"mobipreview.htm?43/3/44093\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Physical disability is common in older adults. In the 1996 National Health Interview Survey, approximately 20 to 30 percent of community-dwelling elders reported disability in mobility, IADLs,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ADLs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/5\">",
"     5",
"    </a>",
"    ]. Many adults, however, can compensate for any disabilities and thrive. Additionally, disability is often reversible",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recurrent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/24\">",
"     24",
"    </a>",
"    ]. Disability is not synonymous with frailty or with FTT.",
"   </p>",
"   <p>",
"    Disability may develop slowly due to progressive comorbidities and frailty, or acutely due to catastrophic events (eg, stroke). Disability is an independent risk factor for mortality, hospitalization, and need for long-term care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neuropsychiatric impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delirium, depression, and dementia are the most common conditions impairing cognitive status in older adults. The evaluation of any patient with FTT should include attention to the signs or symptoms of delirium, dementia, and depression. These conditions may result from medical comorbidities and medication effects; each may also contribute to the development of disability, malnutrition, and frailty.",
"   </p>",
"   <p>",
"    Dementia and depression were among the five leading causes of FTT in a case series of inpatients admitted with FTT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/20\">",
"     20",
"    </a>",
"    ]. Another case series of FTT admissions found \"nervous and mental disorders\" to account for 13 percent of the discharge diagnoses, and 54 percent were found to have cognitive impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Delirium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delirium is defined as an acute disorder of attention and global cognitive function and is commonly seen in hospitalized patients with FTT, since delirium and FTT have overlapping risk factors. Dementia, sensory impairments, severe illness, depression, volume depletion, and medical comorbidities greatly increase the risk for delirium. The presence of delirium adds to the patient's in-hospital morbidity and mortality and complicates the evaluation of FTT by impairing the clinical team's ability to assess for dementia and depression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Dementia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of dementia increases rapidly with age, doubling every decade between the seventh and ninth. Some studies have reported an incidence of dementia as high as 42 percent in seniors &ge;85 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/25\">",
"     25",
"    </a>",
"    ]. Unintentional weight loss has been reported in up to 50 percent of nursing home elders with dementia and approximately 30 percent of non-institutionalized patients with mild to moderate Alzheimer disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with FTT and dementia may require additional workup for undetected disease due to the patient's inability to communicate well or lack of insight into their symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression can be a sole cause, or one of many contributors, to FTT. Depression may lead to disability, malnutrition, and weight loss. Rates of all-cause mortality are higher among elders with depression than their non-depressed counterparts. Depression is common in older adults, with incidence rates ranging from 5 percent in the community to 25 percent in the nursing home population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/27\">",
"     27",
"    </a>",
"    ]. All patients with the FTT syndrome should be assessed for depression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39514?source=see_link\">",
"     \"Diagnosis and management of late-life depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     GENERAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the patient perceived to have FTT includes a comprehensive history and physical exam with directed laboratory and radiologic tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history, a critical component of the evaluation of FTT, should be obtained from both the patient and caregivers and should focus on timing and symptoms of frailty, disability, and neuropsychiatric impairment. An extensive history should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All identified medical and psychiatric comorbidities",
"     </li>",
"     <li>",
"      Medications &mdash; prescribed, over-the-counter medications, and herbal or vitamin supplements",
"     </li>",
"     <li>",
"      Use of alcohol or illicit drugs",
"     </li>",
"     <li>",
"      Comprehensive review of systems for new and",
"      <span class=\"nowrap\">",
"       or/changing",
"      </span>",
"      symptoms",
"     </li>",
"     <li>",
"      Potential contributors to disability, including vision and hearing loss",
"     </li>",
"     <li>",
"      Factors related to poor mobility &mdash; podiatric and arthritic problems, history of falls in last year",
"     </li>",
"     <li>",
"      Factors related to difficulty feeding &mdash; tremor, use of upper extremities, dental problems, xerostomia, odynophagia and dysphagia",
"     </li>",
"     <li>",
"      Symptoms suggesting chronic infection (tuberculosis, bronchiectasis, endocarditis) or malignancy &mdash; fever, sweats, pain, weight loss",
"     </li>",
"     <li>",
"      Factors potentially underlying weight loss &mdash; dysphagia, anorexia, nausea, vomiting, diarrhea, bloating, abdominal pain",
"     </li>",
"     <li>",
"      Musculoskeletal pain symptoms &mdash;",
"      <span class=\"nowrap\">",
"       shoulder/hip",
"      </span>",
"      stiffness suggesting polymyalgia rheumatica; other sources of pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A functional history is essential, documenting the patient's ability to perform ADLs and IADLs. It is also important to try to determine the time of onset of functional deficits and the tempo of decline.",
"   </p>",
"   <p>",
"    An assessment of weight loss and malnutrition involves verification of change in weight and body mass index (BMI). A dietary history should include the patient&rsquo;s access to food, number of daily meals, amount of food eaten, need for assistance with eating, difficulty with chewing, and symptoms of anorexia, early satiety, and dysphagia. The Mini-Nutritional Assessment is a validated tool for diagnosing both malnutrition and risk for malnutrition (",
"    <a class=\"graphic graphic_figure graphicRef79831 \" href=\"mobipreview.htm?5/35/5685\">",
"     figure 2",
"    </a>",
"    ). It is also helpful to observe the patient eating.",
"   </p>",
"   <p>",
"    Patients and their caregivers should be questioned about symptoms of depression and cognitive impairment. The Geriatric Depression Scale (GDS) can be administered quickly in the office and has been validated in patients with mild to moderate cognitive impairment (",
"    <a class=\"graphic graphic_table graphicRef72822 \" href=\"mobipreview.htm?29/22/30060\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/28\">",
"     28",
"    </a>",
"    ]. GDS scores correlate with key sequelae of depression such as decreased pain tolerance, disability, and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/29\">",
"     29",
"    </a>",
"    ]. It is important to ask about somatic complaints associated with depression, including loss of appetite, poor sleep, fatigue, and poor concentration. Somatic symptoms of depression may be difficult to separate from those of medical illness, and referral to a psychiatrist or geriatrician is often helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39514?source=see_link\">",
"     \"Diagnosis and management of late-life depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Caregivers should be asked about patient problems with memory, including repetition of questions, difficulty with handling finances, getting lost in the community, car accidents, and participation in usual activities.",
"   </p>",
"   <p>",
"    A social history should include information about the patient's social network and family supports, living situation, financial resources, education, degree of isolation, and recent deaths or losses. Social isolation is a risk factor for institutionalization and death in elders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/1\">",
"     1",
"    </a>",
"    ]. Social vulnerability with independently associated with increased mortality and increased levels of frailty in a study of two large cohorts of older adults in Canada [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elder mistreatment and neglect is common, and clinicians should be alert for signs of these conditions. A telephone survey of 2010 elders in Boston revealed 3.2 percent had been victims of elder mistreatment at least once since age 65 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/31\">",
"     31",
"    </a>",
"    ]. Red flags for possible elder abuse include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Substance abuse among caregivers",
"     </li>",
"     <li>",
"      Limited social supports",
"     </li>",
"     <li>",
"      Behavioral changes in the presence of the caregiver",
"     </li>",
"     <li>",
"      Unexplained injuries",
"     </li>",
"     <li>",
"      Failure to fill medication prescriptions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient should be questioned privately about mistreatment. Interviewing the suspected abuser is more difficult and may require help from providers with experience in this area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination is used to determine and document the level of physical and cognitive impairment, as well as to look for signs of disease that might lead to impairment. Particular interest should be paid to the following components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vital signs &mdash; including weight and height, and orthostatic blood pressure measurements (heart rate and blood pressure measured supine and standing at one and three minutes)",
"     </li>",
"     <li>",
"      HEENT exam &mdash; complete oral cavity examination for signs of dental abscess, dental caries, poorly fitting dentures, or thrush. Otologic exam for cerumen impaction or otitis. Palpation of temporal arteries and sinuses",
"     </li>",
"     <li>",
"      Neck exam &mdash; palpation for lymphadenopathy and thyroid nodules",
"     </li>",
"     <li>",
"      Breast exam &mdash; rule out masses and axillary lymphadenopathy",
"     </li>",
"     <li>",
"      Rectal exam &mdash;for perirectal abscess, fecal impaction, and occult blood in stool",
"     </li>",
"     <li>",
"      Functional evaluation &mdash; observation of the patient dressing and undressing will give significant clues to range of motion of the shoulders and legs, or to apraxia",
"     </li>",
"     <li>",
"      Office screening tests of vision and hearing",
"     </li>",
"     <li>",
"      Detailed neurological exam &mdash; deep tendon reflexes, muscle strength, tests of proprioception and sensation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The \"Get up and go test\" provides performance information as well as many key components of a neurological exam (",
"    <a class=\"graphic graphic_table graphicRef66046 \" href=\"mobipreview.htm?5/47/5885\">",
"     table 7",
"    </a>",
"    ). The patient is asked to rise from a seated position not using his arms, walk 10 feet, turn, and return to the chair to sit. Normal time to complete the test is 7 to 10 seconds; those who require greater than 10 seconds may be at higher risk for falls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/33\">",
"     33",
"    </a>",
"    ]. Patients who can complete the test in 20 seconds or less are generally independent for basic transfers and able to leave the house unattended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mental status testing should start with an evaluation for attention. If attention is impaired, a workup for delirium should be initiated. The evaluation of cognitive impairment and dementia is discussed separately (",
"    <a class=\"graphic graphic_algorithm graphicRef68789 \" href=\"mobipreview.htm?35/0/35854\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28057?source=see_link\">",
"     \"Evaluation of cognitive impairment and dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Laboratory and other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The suspicion of specific disease states developed through the history and physical exam should guide the selection of tests to be ordered. Initial tests should screen for sources of infection, organ failure, and malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34215/abstract/35\">",
"     35",
"    </a>",
"    ]. Basic laboratory studies to be drawn on all patients with FTT include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CBC with differential",
"     </li>",
"     <li>",
"      Basic metabolic panel (electrolytes, BUN, creatinine, glucose)",
"     </li>",
"     <li>",
"      Liver function studies",
"     </li>",
"     <li>",
"      Urinalysis",
"     </li>",
"     <li>",
"      Calcium, phosphate",
"     </li>",
"     <li>",
"      TSH",
"     </li>",
"     <li>",
"      Vitamin B12 and folate levels",
"     </li>",
"     <li>",
"      Albumin and total cholesterol (the most definitive markers of malnutrition)",
"     </li>",
"     <li>",
"      25 (OH) vitamin D (if history of falls)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additionally, a chest radiograph can assess for tuberculosis, other occult infections, or malignancy. An electrocardiogram may detect silent myocardial infarction or arrhythmia.",
"   </p>",
"   <p>",
"    An erythrocyte sedimentation rate (ESR) or C reactive protein (CRP) level may be considered looking for polymyalgia rheumatica, chronic infection, or malignancy. If risk factors are present, one should consider blood cultures and serologic testing for HIV and syphilis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Consultants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Speech therapists and dietitians can help in the evaluation of unexplained weight loss or malnutrition. Speech therapy may distinguish whether poor oral intake relates to difficulty with swallowing coordination (dementia or stroke), difficulty with chewing (poor dentition or periodontal infection), or difficulty with aspiration. The speech therapy evaluation may lead to therapeutic interventions involving appropriate food textures, positioning, and swallowing techniques. A dietitian can perform a detailed analysis of the patient's current caloric intake and caloric needs for their activity level and illness, leading to therapeutic suggestions.",
"   </p>",
"   <p>",
"    The patient with FTT should also be evaluated by physical and occupational therapy. Physical therapy can assess and advise regarding use of appropriate assistive devices, grab bars and other home safety tools, and rehabilitation therapy. Occupational therapy can evaluate the patient's ability to perform activities of daily living and assist in a cognitive evaluation, recommending appropriate therapy and safety interventions.",
"   </p>",
"   <p>",
"    A skilled social worker can work with families to address social isolation. Social work interventions may include family and patient education regarding dementia and end-of-life issues, referral to community resources, and counseling for depression and bereavement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Failure to thrive (FTT) in older adults is a syndrome of global decline, often associated with physical frailty, functional disability, and neuropsychiatric impairment. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Frailty is defined by the features of weight loss, exhaustion, weakness, slow gait, and decreased physical activity. Medications, medical comorbidities, and socioeconomic factors often play a role (",
"      <a class=\"graphic graphic_table graphicRef68249 \" href=\"mobipreview.htm?23/37/24157\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef59323 \" href=\"mobipreview.htm?5/14/5357\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Frailty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disability is difficulty in performing tasks necessary for self-care (ADLs) and independent living (IADLs). Many adults can compensate for their disability, which is not synonymous with frailty or with FTT. Neuropsychiatric impairment commonly relates to one of three conditions: delirium, dementia, or depression. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Disability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The history should be obtained from the patient and his or her caregivers. In addition to a complete history and review of symptoms, the clinician should explore timing of symptom onset and progression, prescription and over the counter medication use, substance abuse, functional status, depression and cognitive issues, and social history. Signs of elder mistreatment and neglect should be kept in mind. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A comprehensive medical examination should be supplemented by the \"Get up and go test,\" mental status testing, and office-based screening for hearing and vision. Laboratory investigations should be based on suspected underlying diseases. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Laboratory and other studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A multidisciplinary team approach is recommended for patient assessment and might include a speech therapist, dietitian, physical therapist, occupational therapist, and social worker. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Consultants'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/1\">",
"      Sarkisian CA, Lachs MS. \"Failure to thrive\" in older adults. Ann Intern Med 1996; 124:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/2\">",
"      Hamerman D. Toward an understanding of frailty. Ann Intern Med 1999; 130:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/3\">",
"      Braun JV, Wykle MH, Cowling WR 3rd. Failure to thrive in older persons: a concept derived. Gerontologist 1988; 28:809.",
"     </a>",
"    </li>",
"    <li>",
"     Fried LP, Walston J. Frailty and failure to thrive. In: Principles of Geriatric Medicine and Gerontology, 5th ed, Hazzard W, Blass J, Halter J, et al (Eds), McGraw-Hill Professional, 2003. p.1487.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/5\">",
"      Fried LP, Ferrucci L, Darer J, et al. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 2004; 59:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/6\">",
"      Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56:M146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/7\">",
"      Ensrud KE, Ewing SK, Taylor BC, et al. Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med 2008; 168:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/8\">",
"      Ensrud KE, Ewing SK, Cawthon PM, et al. A comparison of frailty indexes for the prediction of falls, disability, fractures, and mortality in older men. J Am Geriatr Soc 2009; 57:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/9\">",
"      Rehman HU. Involuntary Weight Loss in the Elderly. Clin Geriatr 2005; 13:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/10\">",
"      Ritchie CS, Locher JL, Roth DL, et al. Unintentional weight loss predicts decline in activities of daily living function and life-space mobility over 4 years among community-dwelling older adults. J Gerontol A Biol Sci Med Sci 2008; 63:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/11\">",
"      Landi F, Zuccal&agrave; G, Gambassi G, et al. Body mass index and mortality among older people living in the community. J Am Geriatr Soc 1999; 47:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/12\">",
"      Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/13\">",
"      Fine JT, Colditz GA, Coakley EH, et al. A prospective study of weight change and health-related quality of life in women. JAMA 1999; 282:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/14\">",
"      Launer LJ, Harris T, Rumpel C, Madans J. Body mass index, weight change, and risk of mobility disability in middle-aged and older women. The epidemiologic follow-up study of NHANES I. JAMA 1994; 271:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/15\">",
"      Blaum CS, Xue QL, Michelon E, et al. The association between obesity and the frailty syndrome in older women: the Women's Health and Aging Studies. J Am Geriatr Soc 2005; 53:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/16\">",
"      Fabiny AR, Kiel DP. Assessing and treating weight loss in nursing home patients. Clin Geriatr Med 1997; 13:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/17\">",
"      Bouras EP, Lange SM, Scolapio JS. Rational approach to patients with unintentional weight loss. Mayo Clin Proc 2001; 76:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/18\">",
"      Alibhai SM, Greenwood C, Payette H. An approach to the management of unintentional weight loss in elderly people. CMAJ 2005; 172:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/19\">",
"      Berkman B, Foster LW, Campion E. Failure to thrive: paradigm for the frail elder. Gerontologist 1989; 29:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/20\">",
"      Hildebrand JK, Joos SK, Lee MA. Use of the diagnosis \"failure to thrive\" in older veterans. J Am Geriatr Soc 1997; 45:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/21\">",
"      Dharmarajan TS, Akula M, Kuppachi S, Norkus EP. Vitamin D deficiency in community older adults with falls of gait imbalance: an under-recognized problem in the inner city. J Nutr Elder 2005; 25:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/22\">",
"      Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of Vitamin D on falls: a meta-analysis. JAMA 2004; 291:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/23\">",
"      Visser M, Deeg DJ, Puts MT, et al. Low serum concentrations of 25-hydroxyvitamin D in older persons and the risk of nursing home admission. Am J Clin Nutr 2006; 84:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/24\">",
"      Gill TM, Guo Z, Allore HG. Subtypes of disability in older persons over the course of nearly 8 years. J Am Geriatr Soc 2008; 56:436.",
"     </a>",
"    </li>",
"    <li>",
"     Alzheimer's Association. An overview of Alzheimer's disease; general statistics/demographics. Available at: www.alz.org/alzheimers_disease_alzheimer_statistics.asp (Accessed on August 20, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/26\">",
"      White H, Pieper C, Schmader K, Fillenbaum G. Weight change in Alzheimer's disease. J Am Geriatr Soc 1996; 44:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/27\">",
"      NIH consensus conference. Diagnosis and treatment of depression in late life. JAMA 1992; 268:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/28\">",
"      Yesavage JA, Sheikh JI. Geriatric Depression Scale (GDS) recent evidence and development of a shorter violence. Clin Gerontol 1986; 5:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/29\">",
"      Katz IR, DiFilippo S. Neuropsychiatric aspects of failure to thrive in late life. Clin Geriatr Med 1997; 13:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/30\">",
"      Andrew MK, Mitnitski AB, Rockwood K. Social vulnerability, frailty and mortality in elderly people. PLoS One 2008; 3:e2232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/31\">",
"      Pillemer K, Finkelhor D. The prevalence of elder abuse: a random sample survey. Gerontologist 1988; 28:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/32\">",
"      Lachs MS, Pillemer K. Abuse and neglect of elderly persons. N Engl J Med 1995; 332:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/33\">",
"      Podsiadlo D, Richardson S. The timed \"Up &amp; Go\": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991; 39:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/34\">",
"      Robertson RG, Montagnini M. Geriatric failure to thrive. Am Fam Physician 2004; 70:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34215/abstract/35\">",
"      Verdery RB. Clinical evaluation of failure to thrive in older people. Clin Geriatr Med 1997; 13:769.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3018 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-5B3EA195B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_26_34215=[""].join("\n");
var outline_f33_26_34215=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COMPONENTS OF FTT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Frailty",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Weight loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Neuromuscular function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neuropsychiatric impairment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Delirium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Dementia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      GENERAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Laboratory and other studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Consultants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/3018\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/3018|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?35/0/35854\" title=\"algorithm 1\">",
"      Diagnosis of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/3018|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/14/37103\" title=\"figure 1\">",
"      FTT components",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/35/5685\" title=\"figure 2\">",
"      Mini nutritional assesment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/3018|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/36/15948\" title=\"table 1\">",
"      Causes malnutrition elders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/37/24157\" title=\"table 2\">",
"      Meds associated with FTT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/14/5357\" title=\"table 3\">",
"      Causes weight loss and FTT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/13/2269\" title=\"table 4\">",
"      Katz daily living scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/3/44093\" title=\"table 5\">",
"      Lawton daily living scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/22/30060\" title=\"table 6\">",
"      Geriatric depression scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/47/5885\" title=\"table 7\">",
"      Get up and go test",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?39/41/40593?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body mass index (BMI; Quetelet's index)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39514?source=related_link\">",
"      Diagnosis and management of late-life depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/29/42455?source=related_link\">",
"      Failure to thrive in elderly adults: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/4/22602?source=related_link\">",
"      Falls in older persons: Risk factors and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28792?source=related_link\">",
"      Frailty",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_26_34216="ALL monotonous view";
var content_f33_26_34216=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F66656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F66656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute lymphoblastic leukemia in bone marrow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 437px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of this bone marrow aspirate shows a monotonous collection of blast forms, in a patient with acute lymphoblastic leukemia (ALL). Even at this magnification, the cells can be seen to have a high nuclear:cytoplasmic ratio and prominent nucleoli (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_26_34216=[""].join("\n");
var outline_f33_26_34216=null;
var title_f33_26_34217="Treatment of giant cell (temporal) arteritis";
var content_f33_26_34217=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of giant cell (temporal) arteritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/26/34217/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/26/34217/contributors\">",
"     Gene G Hunder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/26/34217/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/26/34217/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/26/34217/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/26/34217/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/26/34217/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/26/34217/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giant cell arteritis (GCA), also known as temporal arteritis, is a chronic vasculitis of medium and large vessels that occurs only in individuals older than 50 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/1\">",
"     1",
"    </a>",
"    ]. The mean age at diagnosis in patients with GCA is 72. Many of the most concerning features of the disease (eg, anterior ischemic optic neuropathy resulting in visual loss) result from vascular inflammation involving cranial branches of the arteries that originate from the aortic arch [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The disease is generalized, however, and may also involve the aorta itself, leading to aneurysms of the thoracic and abdominal aorta and also to ischemic symptoms (claudication) in the extremities.",
"   </p>",
"   <p>",
"    The treatment and prognosis of giant cell arteritis (GCA) are reviewed here. The clinical manifestations and diagnosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34599?source=see_link\">",
"     \"Diagnosis of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179053451\">",
"    <span class=\"h1\">",
"     TREATMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid treatment should be instituted promptly once the diagnosis of GCA is suspected strongly, often even before it is confirmed. For patients in whom the diagnostic suspicion of GCA is high, especially those with recent or threatened vascular complications such as visual loss, therapy should be started immediately. A temporal artery biopsy should be obtained as soon as possible, but treatment should not be withheld while awaiting the performance or the results of the biopsy. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Visual loss at diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34599?source=see_link\">",
"     \"Diagnosis of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the temporal or other artery biopsies reveal no evidence of arteritis but if clinical suspicion of GCA remains strong, glucocorticoid treatment should be continued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/1\">",
"     1",
"    </a>",
"    ]. Even with optimal bilateral temporal artery biopsy performance, false-negative results occur in at least 9 percent of GCA cases and probably in even higher percentages in most settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/4\">",
"     4",
"    </a>",
"    ]. The therapeutic regimen for GCA is somewhat different than that for patients who are believed to have only polymyalgia rheumatica (PMR). In general, the treatment of PMR requires lower doses of glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34599?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnosis of giant cell (temporal) arteritis\", section on 'Temporal artery biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40598?source=see_link\">",
"     \"Treatment of polymyalgia rheumatica\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H9\">",
"     'Glucocorticoid tapering'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179055075\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids have not been studied in a placebo-controlled manner in GCA. Their effectiveness in this disorder is so well-established, however, by years of use and knowledge of the consequences of untreated disease, that it would be unethical to conduct such a study at this time. Evidence for efficacy is based upon several series in which the use of glucocorticoids improved or resolved symptoms and decreased the risk of vascular complications when compared with the rates of such events in patients with the disease prior to the glucocorticoid era [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Daily dosing is more effective than alternate day dosing, but split dosing (ie, the use of multiple doses during a single day) is no more effective than a single daily dose. This was illustrated in a study of an average daily dose of 45 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    given as 15 mg every eight hours, 45 mg once daily, or 90 mg on alternate days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/9\">",
"     9",
"    </a>",
"    ]. The daily regimens were more effective than the alternate dosing as a result of recrudescence of symptoms on the &ldquo;off&rdquo; day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Initial dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;If GCA is not complicated by symptoms or signs of ischemic organ damage (eg, visual loss), we suggest an initial dose of glucocorticoid equivalent to 40 to 60 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    in a single dose. If potentially reversible symptoms persist or worsen, the dose may increase until symptomatic control is achieved. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Efficacy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The optimal dose of glucocorticoids for initial treatment of GCA is uncertain, and the potential benefits in efficacy associated with the use of pulse glucocorticoids at the start of therapy require confirmation in other studies. An initial daily dose of 40 to 60 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or its equivalent in single or divided doses is adequate in almost all cases of GCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/9\">",
"     9",
"    </a>",
"    ]. Some patients respond to doses as low as 20",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    but this dose is seldom used, primarily because of concern for the potential consequences of undertreatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized, double-blind, placebo-controlled trial examined the hypothesis that a remission induction regimen including high-dose pulse intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    would permit a shorter course of therapy compared with a more conventional treatment regimen beginning with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/11\">",
"     11",
"    </a>",
"    ]. Twenty-seven patients with biopsy-proven GCA were randomly assigned to receive either intravenous methylprednisolone (15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for three doses) or intravenous saline. All patients were started on prednisone (40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and followed the same tapering schedule.",
"   </p>",
"   <p>",
"    The following benefits were noted in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    arm:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher rate of sustained remission after cessation of glucocorticoid therapy",
"     </li>",
"     <li>",
"      A greater likelihood of achieving and maintaining daily doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      &le;5 mg at 36, 52, and 78 weeks of follow-up (eg, 10 of 14 patients versus 2 of 13 patients at 36 weeks)",
"     </li>",
"     <li>",
"      A lower median cumulative dose of glucocorticoid, excluding the initial intravenous glucocorticoid dose",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complications were not different between the two groups.",
"   </p>",
"   <p>",
"    Until the results of this small trial are confirmed by additional investigations, we do not suggest using pulse glucocorticoids in patients with uncomplicated disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Visual loss at diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there is a strong suspicion of GCA as the cause of visual loss, we suggest use of intravenous pulse",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    . In this setting, the typical dose is 1000 mg intravenously each day for three days. This is then followed by oral therapy with 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (maximum of 60",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    as recommended above for uncomplicated GCA.",
"   </p>",
"   <p>",
"    Because of the small likelihood of significant visual improvement after anterior ischemic optic neuropathy (AION), prevention of visual loss is essential. For patients with amaurosis fugax, diplopia (caused by ischemia to the extraocular muscles), or other symptoms of significant visual dysfunction, parenteral therapy with glucocorticoids in high doses seems appropriate, even if this approach has not been validated in rigorous studies.",
"   </p>",
"   <p>",
"    High-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    should be continued at the starting dose for at least two but not more than four weeks. Patients usually report dramatic improvements of many GCA symptoms (eg, headache, PMR symptoms) within 24 to 48 hours of glucocorticoid administration. Laboratory measures of disease activity, such as the erythrocyte sedimentation rate (ESR), usually improve substantially within a few days of the institution of therapy, as well. The diagnosis of GCA should be reevaluated in patients who are resistant to adequate glucocorticoid therapy.",
"   </p>",
"   <p>",
"    As noted, we recommend low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in GCA. This is particularly important in patients who have already suffered visual loss in one eye. In addition, for patients without contraindications to anticoagulation,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy in addition to low-dose aspirin may also be considered in this setting; however, there is very little information on the use of warfarin in GCA.",
"   </p>",
"   <p>",
"    Whether parenteral glucocorticoid therapy is more effective than oral administration of these agents for patients with GCA and visual loss is not clear. The stark reality of visual loss in GCA, however, is that patients seldom recover useful vision in an affected eye [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of 84 patients evaluated for variable degrees of GCA-associated visual loss, the diagnosis of GCA was confirmed by temporal artery biopsy, and the visual loss was correlated temporally with the onset of other GCA symptoms. Among the 84 patients, 114 eyes were affected. Anterior ischemic optic neuropathy (AION) was responsible for the visual loss in over 90 percent of the patients studied.",
"     </li>",
"     <li>",
"      Patients who presented with complete visual loss in one eye, with a history of amaurosis fugax, or with evidence of bilateral or rapidly progressive visual involvement received 150 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      intravenously every eight hours for one to three days before starting treatment with oral glucocorticoids (generally 60 to 80",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ). All patients underwent detailed serial examinations, including tests of visual fields (Goldman perimeter) and visual acuity (Snellen).",
"     </li>",
"     <li>",
"      Only 12 eyes (10 percent) belonging to 10 patients showed improvement in visual acuity (defined as an improvement of at least two lines of the Snellen chart). Moreover, only five eyes (4 percent) belonging to five patients had improvement in the central visual field function as well as in visual acuity.",
"     </li>",
"     <li>",
"      The improvement noted in a small number of patients is likely due to a combination of factors, including the subjectivity of the visual field test (which relies heavily both upon cooperation from the patient and upon the skill of the clinician interpreting the results), the inability of the Goldman perimeter test to detect small amounts of visual improvement, and learning by the patient (eg, by fixating eccentrically on the letters in the Snellen chart).",
"     </li>",
"     <li>",
"      In short, &ldquo;improvement&rdquo; perceived by patients and noted on visual acuity tests may not reflect true improvement in retinal or optic nerve function but rather the patient&rsquo;s compensation for acquired, permanent visual deficits.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Polymyalgia rheumatica",
"    </span>",
"    &nbsp;&mdash;&nbsp;PMR, a disorder that forms a spectrum of disease with GCA, is characterized clinically by aching and morning stiffness in the shoulders, hip girdle, neck, and torso. The initial dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    needed to alleviate musculoskeletal symptoms in PMR is lower than that required to control the vascular inflammation associated with GCA. Depending upon the patient&rsquo;s weight and upon the severity of symptoms, a starting dose of prednisone between 10 and 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    may be appropriate. The average starting dose of prednisone is typically 15 mg. The swiftness of the patient&rsquo;s response to prednisone in most PMR cases (within 24 to 48 hours) is highly typical. The absence of such a response is often considered grounds for revisiting the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40598?source=see_link\">",
"     \"Treatment of polymyalgia rheumatica\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of glucocorticoid use in GCA should be anticipated, and the patients should be provided appropriate warnings. Common problems with high doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    include weight gain, glucose intolerance, frank diabetes mellitus, hypertension, opportunistic infection, and osteoporosis. Close follow-up of patients and laboratory monitoring after the institution of treatment are essential to detecting these potential issues early. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of common infections is also increased in patients with GCA who are on glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/13\">",
"     13",
"    </a>",
"    ]. In a cohort study of 1664 patients with GCA on glucocorticoids who were compared with 8078 age- and sex-matched controls, at least one episode of systemic infection was experienced during follow-up by significantly more patients with GCA (48 versus 37 percent). This risk was greatest in the first six months following diagnosis. The risk of serious infection (pneumonia, upper urinary tract infection, and sepsis) was also significantly increased (adjusted rate ratio 1.55, 95% CI 1.22-1.96); the absolute risk was increased by approximately one additional serious infection per 100 patient-years in those with GCA (rate per 100 person-years of 2.27, 95% CI 1.82-2.82, versus 1.29, 95% CI 1.14-1.46).",
"   </p>",
"   <p>",
"    Use of glucocorticoids may also predispose to osteoporosis or may worsen preexisting osteoporosis. This is a particular concern because the disease affects postmenopausal women and older men. Use of calcium supplements, vitamin D, hormone replacement therapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bisphosphonates (in prophylactic or therapeutic doses) are valuable adjuncts to GCA treatment. Bone mineral density measurement is recommended for patients at risk for osteoporosis at the outset of therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=see_link\">",
"     \"Screening for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Glucocorticoid tapering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid tapering can begin once the disease has been controlled adequately. The usual practice is to begin tapering a patient&rsquo;s glucocorticoids after two to four weeks at the starting dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . Although the patient&rsquo;s symptoms are usually controlled promptly by therapy, disease flares are the rule if the glucocorticoids are tapered too quickly. If the initial dose of prednisone is 60",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    it can generally be reduced to 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    after two weeks and to 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    at the end of a month. After that, the dose can be gradually reduced by approximately 10 percent of the total daily dose each one or two weeks. After achieving a daily dose of 10 mg, the prednisone taper should be slowed substantially, such that patients remain on some prednisone (in progressively lower doses) for 9 to 12 months. Tapering in 1 mg decrements each month once the daily dose is less than 10 mg is appropriate.",
"   </p>",
"   <p>",
"    Disease flares at doses higher than 15",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    are distinctly unusual, but flares are very common at doses below that level. The risk of disease flare rises as the daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose declines. Relapses that necessitate an increased glucocorticoid dose often lead to prolonged glucocorticoid treatment. In the setting of one clinical trial, the mean duration of treatment for GCA was 15 to 17 months, and the cumulative prednisone dose was approximately 6 to 6.5 grams [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Monitoring and gauging disease activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most challenging aspects of GCA treatment is identifying flares accurately in the setting of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    tapers. This involves two potentially difficult scenarios: 1) recognizing when recurrent disease is present and 2) recognizing when it is not. Acute phase reactants such as the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are often useful adjuncts to clinical decision-making.",
"   </p>",
"   <p>",
"    Laboratory testing (hemoglobin, ESR, or serum CRP) prior to each decrease in glucocorticoid dose is ideal, but patient convenience or other logistic issues may necessitate testing at other intervals.",
"   </p>",
"   <p>",
"    At some point, the ESR or other monitoring tests may rise above normal, leading to concern about the recurrence of disease activity. In this setting, the clinician must remember that the ESR normally rises somewhat with age (a value of 40",
"    <span class=\"nowrap\">",
"     mm/hour",
"    </span>",
"    may not be abnormal for an 80-year-old) and that treatment must be directed toward the patient, not toward the laboratory value. Nevertheless, anxiety on the part of both patient and clinician may be assuaged by slowing the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    taper in this setting, with subsequent reductions in smaller decrements and in wider intervals. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Relapse'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If abnormal laboratory values such as an elevated ESR or CRP are not accompanied by symptoms or findings suggestive of recrudescent GCA, reflexive changes in the glucocorticoid dose based upon the test results alone may prolong the period of glucocorticoid therapy unnecessarily, may increase the cumulative glucocorticoid dose, and may heighten the likelihood of treatment-related adverse effects.",
"   </p>",
"   <p>",
"    Both the ESR and CRP are imperfect biomarkers in GCA. In general, they are high, often strikingly so, at the time of diagnosis, before the initiation of treatment. In one population-based study, however, 11 percent of patients with biopsy-proven GCA had ESR values &lt;50",
"    <span class=\"nowrap\">",
"     mm/hour",
"    </span>",
"    at the time of diagnosis, even before glucocorticoids had been administered. In some patients, abnormalities of serum proteins unrelated to GCA may elevate the ESR spuriously. Examples include monoclonal gammopathies and hypergammaglobulinemia secondary to liver disease. For such patients, the CRP may be a more useful marker of disease activity.",
"   </p>",
"   <p>",
"    The CRP has not been studied as rigorously in a population-based setting, but clinical experience indicates that it, too, does not always mirror clinical disease activity accurately. The usual practice is to measure both the ESR and the CRP at a patient&rsquo;s visits and to identify, through longitudinal follow-up, which of these measurements, if either, appears to reflect disease activity with some faithfulness. With the ESR and CRP, mild elevations even into the &ldquo;abnormal&rdquo; range for most laboratories are not unusual as the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    taper proceeds. In such settings, the clinician must remember to treat the patient and not to treat the laboratory test result. Reflex increases in a patient&rsquo;s prednisone dose in response to acute phase reactant elevations often lead to substantial glucocorticoid morbidity.",
"   </p>",
"   <p>",
"    Monitoring of serum levels of interleukin (IL)-6 and of soluble intercellular adhesion molecule (sICAM)-1 holds promise as additional potential assays to assess active disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. In one study, clinical relapse correlated more closely with serum levels of interleukin-6 than with the erythrocyte sedimentation rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/62/8166?source=see_link\">",
"     \"Pathogenesis of giant cell (temporal) arteritis\"",
"    </a>",
"    .) However, in clinical practice, the ESR and CRP are the laboratory measures that are used routinely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recrudescence of GCA should be suspected when patients have a return of symptoms that recall their original presentations, when new symptoms compatible with the diagnosis of GCA or PMR occur, or when there is a striking elevation of acute phase reactants. ESR or CRP elevation does not always indicate a disease flare, but observation of one of these laboratory changes should trigger close clinical follow-up and questioning of patients about symptoms of possible disease recurrences.",
"   </p>",
"   <p>",
"    Patients should be counseled to be watchful for symptoms of PMR or GCA and should be encouraged to seek medical attention immediately if any symptoms are noted. Patient information about PMR and GCA is presented separately. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/54/42852?source=see_link\">",
"     \"Patient information: Polymyalgia rheumatica and giant cell (temporal) arteritis (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For aortic aneurysms between 3 and 5 cm in diameter which are enlarging and whose presence is associated with markers of inflammation (eg, increased ESR or CRP), reinitiation or an increase in the dose of glucocorticoids is warranted. Use of immunosuppressive agents other than glucocorticoids in this setting is not supported by any clinical studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179054602\">",
"    <span class=\"h2\">",
"     Antiplatelet therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon a series of observations and upon the relatively low risk of adverse events with low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , we recommend that all patients with GCA be treated with low-dose aspirin (81 to 100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    to reduce the risk of visual loss, transient ischemic attacks, or stroke.",
"   </p>",
"   <p>",
"    In view of the concomitant use of glucocorticoids, the prevention of gastroduodenal damage with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    or a proton pump inhibitor is prudent in such patients, most of whom are older and are at increased risk of complications in the event of ulcer bleeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three considerations provide the rationale for employing antiplatelet therapy in GCA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the event leading to visual loss in AION is profound intimal hyperplasia rather than a classic thrombotic event, in theory, platelet inhibition may lessen the thrombotic risks associated with greatly narrowed vascular lumina of the posterior ciliary and ophthalmic arteries.",
"     </li>",
"     <li>",
"      In a mouse chimera model of GCA (temporal arteries from humans with GCA were grafted onto immunodeficient mice), salicylates inhibited interferon gamma, a primary inflammatory mediator of GCA, much more effectively than did glucocorticoids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There may be an increased risk of visual loss in patients with GCA and thrombocytosis, leading some to suggest the addition of antiplatelet agents in patients with platelet counts above",
"      <span class=\"nowrap\">",
"       400,000/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two retrospective cohort studies demonstrated substantial reductions in odds ratios for visual loss and cerebral ischemic events in patients with GCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. One of the studies reviewed 175 patients with GCA, 36 of whom were taking low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for cardiovascular disease prior to the diagnosis of GCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/20\">",
"     20",
"    </a>",
"    ]. All patients were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of cranial ischemic events at presentation was significantly lower in those taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      at baseline (8 versus 29 percent, odds ratio 0.22).",
"     </li>",
"     <li>",
"      An additional 41 patients were begun on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      after diagnosis. In the three months following the diagnosis of GCA, cranial ischemic events were less common in the aspirin group (3 versus 13 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar benefits were noted in another respective study of 143 patients. Sixty percent were treated with an antiplatelet agent (mostly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ; among these patients, 20 percent were begun on such therapy because of a prior ischemic event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/21\">",
"     21",
"    </a>",
"    ]. The rate of ischemic events was much lower in the patients treated with aspirin or warfarin (16 versus 48 percent, adjusted odds ratio 0.18 for aspirin and 0.17 for warfarin).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H987590472\">",
"    <span class=\"h2\">",
"     Other measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional monitoring and interventions to prevent complications of disease and of therapy should be initiated at the beginning of treatment. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prophylaxis versus bone mineral loss &mdash; Because treatment courses with glucocorticoids of one to two years are normal in GCA, osteoporosis prevention must be considered at the start of therapy. Adequate dietary calcium and vitamin D intake should be encouraged. Bisphosphonate use, either for prophylaxis or for treatment, may also be appropriate. Determination of bone mineral density near the time that treatment is initiated may be valuable in guiding prophylaxis or treatment for osteoporosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Monitoring for development of aortic aneurysm &mdash; A significant minority of patients with GCA develop aortic aneurysms, involving the ascending more often than the descending aorta [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/22\">",
"       22",
"      </a>",
"      ]. We recommend that yearly chest x-rays should be performed for up to 10 years to identify patients with thoracic aortic aneurysms prior to rupture or dissection. If aneurysmal dilatation is detected, monitoring with computer-aided tomography every 6 to 12 months is recommended. Medical management is indicated for thoracic aneurysms between 3 and 5 cm in diameter, while surgical treatment may be considered for patients with larger or rapidly enlarging aneurysms. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/7/10361?source=see_link\">",
"       \"Management and outcome of thoracic aortic aneurysm\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179055083\">",
"    <span class=\"h1\">",
"     RESISTANT DISEASE AND GLUCOCORTICOID-SPARING AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who have developed or who are at high risk for adverse effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) may be a possible glucocorticoid-sparing strategy. Other alternatives for such patients and for those with resistant disease include the interleukin (IL)-6 blocker,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . Information regarding the use of MTX, tocilizumab, and cyclophosphamide in GCA is limited. In addition, one small trial of the tumor necrosis factor (TNF) inhibitor,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , showed no effectiveness. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Methotrexate as a glucocorticoid-sparing agent'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13\">",
"     'Infliximab'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Methotrexate as a glucocorticoid-sparing agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of three randomized trials that compared the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) with placebo in patients with GCA being treated with glucocorticoids have led to somewhat divergent conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. A meta-analysis of the individual patient-level data from these three trials involving a total of 161 patients suggested that the use of MTX resulted in a significant reduction in the cumulative dose of glucocorticoid over the 48 weeks following randomization (cumulative dose reduction of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or equivalent of 842 mg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/26\">",
"     26",
"    </a>",
"    ]. MTX treatment was associated with a higher probability of achieving sustained discontinuation of glucocorticoids during follow-up and with fewer relapses. Comparison of reported adverse events did not reveal any significant differences between the treatment groups. The superiority of MTX over placebo appeared only after 24 to 36 weeks.",
"   </p>",
"   <p>",
"    The results of these trials suggest, at best, that MTX is moderately effective as a glucocorticoid-sparing agent and that additional work toward the identification of an effective",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    -sparing agent is essential. The routine addition of MTX to glucocorticoid therapy for GCA is not recommended. However, among patients who have developed or who are at high risk for adverse effects of prednisone, the addition of MTX may be considered as a possible glucocorticoid-sparing strategy.",
"   </p>",
"   <p>",
"    The range of evidence is illustrated by the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multinational, randomized, placebo-controlled trial in 98 patients with GCA (83 percent of whom had positive temporal artery biopsies) found no significant impact of the addition of MTX to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/23\">",
"       23",
"      </a>",
"      ]. The two treatment arms consisted of oral MTX (0.15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per week) or placebo in addition to prednisone (initial dose of 1 mg per kg per day, maximum of 60 mg per day). After 12 months of observation, there was no significant difference between the two groups, with treatment failures occurring in 57 and 77 percent of the MTX and placebo groups, respectively (relative risk of treatment failure in the MTX group 0.72; 95% CI 0.41-1.28).",
"      <br/>",
"      <br/>",
"      There are two points that should be considered related to the apparent lack of benefit of MTX in this trial and to the high proportion of patients who experienced disease flares. First, the 20 percent difference in treatment failures between the groups, if sustained with a larger number of patients (eg, a total of 300, as the study was originally conceived), would have achieved statistical significance. Second, the trial employed an alternate-day glucocorticoid taper after the first three months, an approach not utilized by most clinicians in practice.",
"     </li>",
"     <li>",
"      In the second major randomized trial of MTX in GCA, 42 patients with biopsy-proven GCA were assigned randomly to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      plus either MTX (at 10",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/24\">",
"       24",
"      </a>",
"      ]. Compared with the placebo group, patients receiving MTX were less likely to relapse (45 and 84 percent), had a shorter time to complete withdrawal of prednisone (median time of 29 and 94 weeks), and had a lower mean cumulative dose of prednisone (4.2 and 5.5 grams). In contrast to the study by Hoffman et al [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/23\">",
"       23",
"      </a>",
"      ], this study used less MTX and did not employ alternate-day glucocorticoid tapering.",
"     </li>",
"     <li>",
"      A third trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/25\">",
"       25",
"      </a>",
"      ] included 21 patients with GCA, with 12 randomized to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and with nine randomized to placebo. No glucocorticoid-sparing benefit could be attributed to the combination of methotrexate with glucocorticoid therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179055212\">",
"    <span class=\"h2\">",
"     Tocilizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several case series and case reports have reported that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    (TCZ) may be effective in patients with GCA in whom it has been difficult to taper glucocorticoids to an acceptable level or in whom disease has been refractory or relapsing, even despite therapy with additional agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. The use of TCZ in GCA is also supported by the evidence that IL-6 may be important in disease pathogenesis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/62/8166?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathogenesis of giant cell (temporal) arteritis\", section on 'Role of the immune system and cytokines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the largest of these studies, seven patients with GCA, two patients with Takayasu arteritis, and one with PMR (all of whom had relapsing or refractory disease) were treated for a mean period of 7.8 months with TCZ (8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once monthly in eight patients, administered intravenously, and 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once monthly in two of the patients with GCA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/27\">",
"     27",
"    </a>",
"    ]. Clinical improvement was seen within 8 to 12 weeks, and clinical remission was achieved during therapy by all patients.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    doses were decreased significantly (from a mean dose before TCZ of 20.8 mg daily to 4.1 mg daily while receiving TCZ). Acute phase reactants were also markedly reduced by TCZ treatment. One patient flared two months after discontinuation of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    . Four patients had mild neutropenia and transaminitis; one patient without clinical signs of disease but with severe atherosclerotic coronary artery disease died of a postoperative myocardial infarction and was found to have active GCA of multiple large arteries on postmortem examination.",
"   </p>",
"   <p>",
"    Several of the studies documented reduced inflammation in the large vessels by use of either magnetic resonance angiography or by use of [",
"    <sup>",
"     18",
"    </sup>",
"    F]-fluorodeoxyglucose positron emission tomography-computerized tomography (PET-CT) scanning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. Data from randomized trials and long-term follow-up would be helpful to more fully assess the degree of benefit that TCZ may provide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179055220\">",
"    <span class=\"h2\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    (CYC) has been widely used in the treatment of systemic vasculitis. Two small, uncontrolled studies have suggested that it may be useful in GCA in patients at high risk of glucocorticoid-related adverse effects who have not responded adequately to other immunosuppressive or immunomodulatory glucocorticoid-sparing treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In one series of 19 patients (15 with refractory or relapsing disease and four at high risk of adverse effects from glucocorticoids due to diabetes), CYC (median dose of 100 mg daily administered orally) was beneficial in 15 of 19 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/32\">",
"     32",
"    </a>",
"    ]. Remission was achieved in 12 of 13 patients 6 to 12 months after completion of CYC treatment, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    doses were significantly reduced in most patients. MTX (10 to 20 mg once weekly) was administered upon discontinuation of CYC in most patients. Four patients relapsed after therapy was discontinued, and the drug was stopped in one patient due to inefficacy, in three due to side effects, and in one due to both inefficacy and side effects.",
"   </p>",
"   <p>",
"    Adverse effects were common, occurring in nine patients, but were usually reversible with dose reduction or with drug discontinuation. However, one patient died of acute hepatitis due to the CYC therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Infliximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because GCA is characterized by granulomatous inflammation, tumor necrosis factor (TNF) inhibition would appear to be an appropriate treatment approach. However, the only randomized trial of TNF inhibition did not demonstrate efficacy of this intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/34\">",
"     34",
"    </a>",
"    ]. Forty-four patients were studied in a multicenter, randomized, placebo-controlled trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    (a chimeric monoclonal antibody inhibitor of TNF) versus placebo for the maintenance of remission. After",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    -induced remission, patients were randomly assigned in a 2:1 ratio (infliximab 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    versus placebo) to receive infusions at weeks zero, two, and six, with infusions every eight weeks thereafter. Prednisone doses were tapered according to protocol. The two co-primary endpoints were the proportion of relapse-free patients through week 22 and the incidence of adverse events.",
"   </p>",
"   <p>",
"    Sixteen patients were assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    plus placebo, and 28 were assigned to prednisone plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    . An interim analysis at week 22 demonstrated that infliximab did not reduce the proportion of patients with relapses when compared with placebo (43 versus 50 percent). In addition, infliximab did not increase the proportion of patients whose prednisone dose could be tapered to 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    without relapse (61 versus 75 percent). Consequently, the trial was stopped early. Through the follow-up period, no differences between the treatment groups were observed in the proportion of relapse-free patients, in the cumulative dose of prednisone, or in the incidence of adverse events. The investigators concluded that the addition of infliximab to glucocorticoids did not improve the durability of remissions, nor did it reduce cumulative glucocorticoid requirements in GCA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     IS REVASCULARIZATION INDICATED?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Revascularization of arteries to the extremities (eg, angioplasty, stent placement, or bypass surgery) is seldom required in GCA because of the exuberant collateral circulation that occurs in this disease (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73553 \" href=\"mobipreview.htm?6/12/6343\">",
"     image 1",
"    </a>",
"    ). In concert with the narrowing of large arteries, such as the subclavian, through involvement of GCA, an extensive web of small collateral vessels develops. These collaterals are nearly always sufficient to maintain the viability of distal tissues, even though the large pulses (brachial, radial, and ulnar) may be lost and even though some limb claudication may ensue prior to treatment. Only in exceptional circumstances (eg, the development of a subclavian steal syndrome) should thoughts of revascularization be entertained. Through inhibition of the inflammatory process and through allowance of collateral blood vessel growth, most symptoms of large vessel narrowing improve with medical therapy alone. In a small number of cases, successful revascularization has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/35-39\">",
"     35-39",
"    </a>",
"    ]. Restenosis, however, is common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many patients, GCA tends to run a self-limited course over several months to several years. The glucocorticoid dose can eventually be reduced and discontinued in the majority of patients, although a sizable minority have more chronic disease and require low doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    for a number of years to control symptoms.",
"   </p>",
"   <p>",
"    GCA may not adversely affect overall survival. One study with a mean follow-up period of seven years found that the long-term survival of 205 patients with GCA was the same as that of the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Visual loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Permanent partial or complete loss of vision in one or both eyes has been observed in 15 to 20 percent of patients in most series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/19,41\">",
"     19,41",
"    </a>",
"    ]. Frequently, the visual loss occurs prior to presentation. The new onset of visual loss is unusual once treatment with glucocorticoids has begun. This was illustrated in one study of 245 patients with GCA among whom 34 (14 percent) had permanent loss of vision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/41\">",
"     41",
"    </a>",
"    ]. In 32 of the 34 patients (94 percent), the visual loss preceded glucocorticoid therapy. In only two patients did the visual loss develop after glucocorticoid treatment was initiated.",
"   </p>",
"   <p>",
"    The risk of visual loss developing after initiation of glucocorticoid therapy is estimated to be 1 percent for those with no preceding loss of vision. Additional or progressive loss of vision is more frequent in those with impaired vision due to GCA prior to treatment. In such patients, the risk is estimated to be 13 percent in the subsequent five years. Another risk factor for loss of vision is advanced age, defined in one study as &ge;80 years, which may be associated with an increased risk of developing irreversible complete bilateral visual loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The influence of the ESR on the risk of visual loss is uncertain. Two studies of patients with biopsy-proven GCA concluded that patients with lower ESRs were at higher risk of visual loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. In contrast, a subsequent study noted an incidence of visual loss of 21 percent in the subset of patients with biopsy proven GCA and with ESRs between 70 and 100",
"    <span class=\"nowrap\">",
"     mm/hour,",
"    </span>",
"    while the risk of visual loss in those with ESRs less than 70",
"    <span class=\"nowrap\">",
"     mm/hour",
"    </span>",
"    was only 7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/45\">",
"     45",
"    </a>",
"    ]. The reason for the discordant results of these studies is not readily apparent.",
"   </p>",
"   <p>",
"    Some investigators have noted an association between thrombocytosis and visual loss due to ischemic anterior optic neuropathy. As an example, among 174 patients with GCA, 23 (13 percent) developed permanent visual loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34217/abstract/19\">",
"     19",
"    </a>",
"    ]. In these patients, prior transient visual symptoms and thrombocytosis were present approximately sixfold and fourfold more frequently, respectively, than in those whose did not suffer permanent visual loss. The presence of constitutional symptoms or frank PMR may be associated with a reduced risk of blindness, either because patients with these symptoms have a different disease phenotype from those with predominantly cranial symptoms or because the occurrence of such symptoms may lead to earlier diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/24/42369?source=see_link\">",
"       \"Patient information: Polymyalgia rheumatica and giant cell arteritis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/22/44389?source=see_link\">",
"       \"Patient information: Vasculitis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/54/42852?source=see_link\">",
"       \"Patient information: Polymyalgia rheumatica and giant cell (temporal) arteritis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H736599572\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients in whom giant cell arteritis (GCA) is not complicated by symptoms or signs of ischemic organ damage (eg, visual loss), we suggest an initial dose of glucocorticoid equivalent to 40 to 60 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      in a single dose (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If potentially reversible symptoms persist or worsen, the dose may increase until symptomatic control is achieved.",
"     </li>",
"     <li>",
"      If the initial dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      was 60",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      it can generally be reduced to 50",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      after two weeks and to 40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      at the end of a month. After that, the dose can be gradually reduced by approximately 10 percent of the total daily dose each one or two weeks. After achieving a daily dose of 10 mg, the prednisone taper should be slowed substantially, such that patients remain on some prednisone (in progressively lower doses) for 9 to 12 months. Tapering in 1 mg decrements per month once the daily dose is less than 10 mg is appropriate. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Glucocorticoid tapering'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H179053451\">",
"       'Treatment approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory testing (hemoglobin, erythrocyte sedimentation rate, or serum C-reactive protein) prior to each decrease in glucocorticoid dose is ideal, but patient convenience or other logistic issues may necessitate testing at other intervals. The ESR normally rises somewhat with age, and treatment must be directed toward the patient&rsquo;s signs and symptoms and not toward the laboratory value. Nevertheless, the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      taper may be slowed in this setting, with subsequent reductions in smaller decrements and wider intervals. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Monitoring and gauging disease activity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Relapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the addition of low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (80 to 100",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      therapy in patients with GCA with or without visual loss to reduce the risk of visual loss, transient ischemic attacks, or stroke (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In view of the concomitant use of glucocorticoids and aspirin, the prevention of gastroduodenal damage (eg, with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      or a proton pump inhibitor) is prudent in such patients, most of whom are older and are at increased risk of complications in the event of ulcer bleeding. (See",
"      <a class=\"local\" href=\"#H179054602\">",
"       'Antiplatelet therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=see_link\">",
"       \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If there is a strong suspicion of GCA as the cause of visual loss, we suggest use of intravenous pulse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In this setting, the typical dose is 1000 mg intravenously each day for three days. This is then followed by oral therapy with 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (maximum of 60",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      as recommended above for uncomplicated GCA. For patients without contraindications to anticoagulation,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy in addition to low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      may also be considered in this setting.",
"     </li>",
"     <li>",
"      Appropriate measures should be taken at the start of therapy for the prevention of glucocorticoid-induced osteoporosis, such as adequate dietary calcium and vitamin D intake, as well as bisphosphonate therapy. (See",
"      <a class=\"local\" href=\"#H987590472\">",
"       'Other measures'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The addition of MTX can be considered together with glucocorticoids in patients at highest risk of experiencing glucocorticoid-related side effects. Other agents that may be of benefit include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Methotrexate as a glucocorticoid-sparing agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A significant minority of patients with GCA develop aortic aneurysms, involving the ascending more often than the descending aorta. We recommend that yearly chest radiographs should be performed for up to 10 years to identify patients with thoracic aortic aneurysms prior to rupture or dissection. If aneurysmal dilatation is detected, monitoring with computer aided tomography every 6 to 12 months is recommended. (See",
"      <a class=\"local\" href=\"#H987590472\">",
"       'Other measures'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/7/10361?source=see_link\">",
"       \"Management and outcome of thoracic aortic aneurysm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      GCA tends to run a self-limited course over several months to several years. The glucocorticoid dose can eventually be reduced and discontinued in the majority of patients, although a sizable minority of patients have more chronic disease and require low doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      for a number of years to control symptoms. GCA may not adversely affect overall survival. Permanent partial or complete loss of vision in one or both eyes has been observed in 15 to 20 percent of patients in most series. The new onset of visual loss is unusual once treatment with glucocorticoids has begun; it is estimated to be 1 percent for those with no preceding loss of vision. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Prognosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Visual loss'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Hunder GG. Giant cell arteritis and polymyalgia rheumatica. In: Textbook of Rheumatology, 5th, Kelly WN, Harris ED, Ruddy S, Sledge CB (Eds), WB Saunders, Philadelphia 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/2\">",
"      Evans JM, Bowles CA, Bjornsson J, et al. Thoracic aortic aneurysm and rupture in giant cell arteritis. A descriptive study of 41 cases. Arthritis Rheum 1994; 37:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/3\">",
"      Klein RG, Hunder GG, Stanson AW, Sheps SG. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med 1975; 83:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/4\">",
"      Hall S, Persellin S, Lie JT, et al. The therapeutic impact of temporal artery biopsy. Lancet 1983; 2:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/5\">",
"      Salvarani C, Macchioni PL, Tartoni PL, et al. Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol 1987; 5:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/6\">",
"      Delecoeuillerie G, Joly P, Cohen de Lara A, Paolaggi JB. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis 1988; 47:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/7\">",
"      Lundberg I, Hedfors E. Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis. J Rheumatol 1990; 17:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/8\">",
"      Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis 1989; 48:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/9\">",
"      Hunder GG, Sheps SG, Allen GL, Joyce JW. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med 1975; 82:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/10\">",
"      Myles AB, Perera T, Ridley MG. Prevention of blindness in giant cell arteritis by corticosteroid treatment. Br J Rheumatol 1992; 31:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/11\">",
"      Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 2006; 54:3310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/12\">",
"      Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 2002; 80:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/13\">",
"      Durand M, Thomas SL. Incidence of infections in patients with giant cell arteritis: a cohort study. Arthritis Care Res (Hoboken) 2012; 64:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/14\">",
"      Foroozan R, Deramo VA, Buono LM, et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology 2003; 110:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/15\">",
"      Roche NE, Fulbright JW, Wagner AD, et al. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993; 36:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/16\">",
"      Macchioni P, Boiardi L, Meliconi R, et al. Elevated soluble intercellular adhesion molecule 1 in the serum of patients with polymyalgia rheumatica: influence of steroid treatment. J Rheumatol 1994; 21:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/17\">",
"      Weyand CM, Fulbright JW, Hunder GG, et al. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000; 43:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/18\">",
"      Weyand CM, Kaiser M, Yang H, et al. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 2002; 46:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/19\">",
"      Liozon E, Herrmann F, Ly K, et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 2001; 111:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/20\">",
"      Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004; 50:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/21\">",
"      Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 2006; 54:3306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/22\">",
"      Garc&iacute;a-Mart&iacute;nez A, Hern&aacute;ndez-Rodr&iacute;guez J, Arguis P, et al. Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthritis Rheum 2008; 59:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/23\">",
"      Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002; 46:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/24\">",
"      Jover JA, Hern&aacute;ndez-Garc&iacute;a C, Morado IC, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/25\">",
"      Spiera RF, Mitnick HJ, Kupersmith M, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 2001; 19:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/26\">",
"      Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007; 56:2789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/27\">",
"      Unizony S, Arias-Urdaneta L, Miloslavsky E, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken) 2012; 64:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/28\">",
"      Seitz M, Reichenbach S, Bonel HM, et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011; 141:w13156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/29\">",
"      Beyer C, Axmann R, Sahinbegovic E, et al. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis 2011; 70:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/30\">",
"      Salvarani C, Magnani L, Catanoso M, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 2012; 51:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/31\">",
"      Sciascia S, Rossi D, Roccatello D. Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis. J Rheumatol 2011; 38:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/32\">",
"      Quartuccio L, Maset M, De Maglio G, et al. Role of oral cyclophosphamide in the treatment of giant cell arteritis. Rheumatology (Oxford) 2012; 51:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/33\">",
"      Henes JC, Mueller M, Pfannenberg C, et al. Cyclophosphamide for large vessel vasculitis: assessment of response by PET/CT. Clin Exp Rheumatol 2011; 29:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/34\">",
"      Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007; 146:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/35\">",
"      Do DD, Jeanneret C, Mahler F. Images in vascular medicine. Giant cell arteritis of axillary artery. Vasc Med 1996; 1:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/36\">",
"      Monte R, Gonz&aacute;lez-Gay MA, Garc&iacute;a-Porr&uacute;a C, et al. Successful response to angioplasty in a patient with upper limb ischaemia secondary to giant cell arteritis. Br J Rheumatol 1998; 37:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/37\">",
"      Dellaripa PF, Eisenhauer AC. Bilateral percutaneous balloon angioplasty of the axillary arteries in a patient with giant cell arteritis and upper extremity ischemic symptoms not responsive to corticosteroids. J Rheumatol 1998; 25:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/38\">",
"      Amann-Vesti BR, Koppensteiner R, Rainoni L, et al. Immediate and long-term outcome of upper extremity balloon angioplasty in giant cell arteritis. J Endovasc Ther 2003; 10:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/39\">",
"      Both M, Aries PM, M&uuml;ller-H&uuml;lsbeck S, et al. Balloon angioplasty of arteries of the upper extremities in patients with extracranial giant-cell arteritis. Ann Rheum Dis 2006; 65:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/40\">",
"      Matteson EL, Gold KN, Bloch DA, Hunder GG. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med 1996; 100:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/41\">",
"      Aiello PD, Trautmann JC, McPhee TJ, et al. Visual prognosis in giant cell arteritis. Ophthalmology 1993; 100:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/42\">",
"      Liozon E, Loustaud-Ratti V, Ly K, et al. Visual prognosis in extremely old patients with temporal (giant cell) arteritis. J Am Geriatr Soc 2003; 51:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/43\">",
"      Salvarani C, Cimino L, Macchioni P, et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 2005; 53:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/44\">",
"      Cid MC, Font C, Oristrell J, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998; 41:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34217/abstract/45\">",
"      Lopez-Diaz MJ, Llorca J, Gonzalez-Juanatey C, et al. The erythrocyte sedimentation rate is associated with the development of visual complications in biopsy-proven giant cell arteritis. Semin Arthritis Rheum 2008; 38:116.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8240 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-FDF33D9AD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_26_34217=[""].join("\n");
var outline_f33_26_34217=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H736599572\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179053451\">",
"      TREATMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179055075\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Initial dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Visual loss at diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Polymyalgia rheumatica",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Glucocorticoid tapering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Monitoring and gauging disease activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179054602\">",
"      Antiplatelet therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H987590472\">",
"      Other measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179055083\">",
"      RESISTANT DISEASE AND GLUCOCORTICOID-SPARING AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Methotrexate as a glucocorticoid-sparing agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179055212\">",
"      Tocilizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179055220\">",
"      Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Infliximab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      IS REVASCULARIZATION INDICATED?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Visual loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H736599572\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/8240\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8240|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?6/12/6343\" title=\"diagnostic image 1\">",
"      Left subclavian artery GCA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34599?source=related_link\">",
"      Diagnosis of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/7/10361?source=related_link\">",
"      Management and outcome of thoracic aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/62/8166?source=related_link\">",
"      Pathogenesis of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/54/42852?source=related_link\">",
"      Patient information: Polymyalgia rheumatica and giant cell (temporal) arteritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/24/42369?source=related_link\">",
"      Patient information: Polymyalgia rheumatica and giant cell arteritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/22/44389?source=related_link\">",
"      Patient information: Vasculitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40598?source=related_link\">",
"      Treatment of polymyalgia rheumatica",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_26_34218="Primer on interpretation of HIV drug resistance testing";
var content_f33_26_34218=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primer on interpretation of HIV drug resistance testing",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/26/34218/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/26/34218/contributors\">",
"     Calvin J Cohen, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/26/34218/contributors\">",
"     Joel E Gallant, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/26/34218/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/26/34218/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/26/34218/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/26/34218/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/26/34218/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventing and managing antiretroviral (ARV) drug resistance is among the greatest challenges in maintaining durable HIV suppression for the lifetime of an infected patient. Clinicians need to become knowledgeable regarding the resistance patterns associated with specific antiretroviral medications so that they may appropriately select treatment regimens, which will maximize the likelihood of viral suppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/1\">",
"     1",
"    </a>",
"    ]. While these patterns can be complex, there are basic principles that underlie effective utilization of resistance data, which should be considered when making decisions about switching drug regimens after virologic failure.",
"   </p>",
"   <p>",
"    This topic will address the major resistance patterns found in association with different medications and how that knowledge translates into the selection of appropriate treatment regimens. The details in this topic refer mainly to resistance patterns seen with HIV subtype B, which is the most prevalent clade in the United States, Europe, Japan, Thailand and Australia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21546?source=see_link\">",
"     \"The global human immunodeficiency virus pandemic\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21546?source=see_link&amp;anchor=H2#H2\">",
"     \"The global human immunodeficiency virus pandemic\", section on 'Origin of the HIV epidemic'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Types of resistance tests and indications for their use are discussed elsewhere, as are factors that contribute to the emergence of drug resistance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/46/3814?source=see_link\">",
"     \"Clinical trials of HIV drug resistance testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/48/4873?source=see_link\">",
"     \"Overview of HIV drug resistance testing assays\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The selection of antiretroviral therapy (ART) for the treatment-naive or treatment-experienced patient is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link&amp;anchor=H27#H27\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\", section on 'Integrase strand transfer inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27994?source=see_link&amp;anchor=H7365479#H7365479\">",
"     \"Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection\", section on 'Resistance to integrase strand transfer inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19101617\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the initiation of antiretroviral therapy (ART), clinicians must obtain a careful medication history in order to be aware of any possibility of prior resistance from previous drug exposure.",
"   </p>",
"   <p>",
"    Resistance testing, using genotypic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    phenotypic assays, is also invaluable in guiding treatment decisions, whether it is in the treatment-naive or treatment-experienced patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/2\">",
"     2",
"    </a>",
"    ]. A treatment-naive patient may have been infected with drug-resistant virus, while the treatment-experienced patient may have developed resistance as a result of non-suppressive ART. Understanding the implications of the resistance patterns for specific medications and drug classes is important for optimal patient management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/48/4873?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of HIV drug resistance testing assays\", section on 'Phenotypic resistance assays'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/48/4873?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of HIV drug resistance testing assays\", section on 'Genotypic resistance assays'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians also need to be aware that traditional assays (eg, population sequencing) do not detect the presence of low-frequency (eg, minority) drug resistance mutations in an infected individual, which may be detected by more sensitive tests (eg, allele-specific polymerase chain reaction or deep sequencing). Thus, the absence of drug resistance on a standard assay does not rule out the possibility of underlying drug resistance, which can compromise virologic outcomes. For example, in treatment-naive patients initiating nonnucleoside reverse transcriptase inhibitors (NNRTIs), the presence of low frequency variants can increase the risk of virologic failure, particularly in the setting of suboptimal adherence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, the best way to avoid drug resistance is to maintain viral suppression, defined as a viral load below the detection limit of an ultrasensitive viral load assay (ie, &lt;20 to 75",
"    <span class=\"nowrap\">",
"     copies/mL).",
"    </span>",
"    Drug resistance occurs when viral replication continues in the face of ongoing drug pressure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27994?source=see_link\">",
"     \"Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF RESISTANCE TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two types of resistance tests are available: genotypic and phenotypic tests. Genotypic tests identify mutations in the viral genes targeted by antiviral drugs. Phenotypic tests provide a quantitative assessment of drug susceptibility in vitro.",
"   </p>",
"   <p>",
"    Interpreting complex genotypes can be challenging in treatment-experienced patients with multiple resistance mutations. This is particularly true for the protease inhibitors (PIs). In such cases, phenotypic resistance testing may offer an advantage over genotypic testing, as it measures resistance more directly and can assess relative susceptibility and interactions among mutation. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/48/4873?source=see_link\">",
"     \"Overview of HIV drug resistance testing assays\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     BASIC TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following content addresses the various terms that are used in describing drug resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19102023\">",
"    <span class=\"h2\">",
"     Wild-type virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Wild-type\" virus refers to the original parent virus that was predominant prior to the use of antiretroviral medications. A patient may become infected by either a wild-type or a resistant strain. As there are many variant strains of HIV that exist among infected patients that are considered \"wild type\", all are compared to a reference strain in laboratories that perform drug resistance testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19102152\">",
"    <span class=\"h2\">",
"     Viral fitness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral fitness generally refers to the ability of one virus to out-compete a second virus in a defined environment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/4\">",
"     4",
"    </a>",
"    ]. In the setting of drug pressure, drug-resistant virus will have an advantage over wild-type virus. When drug pressure is removed, wild-type virus often replaces mutant virus, which is generally less fit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19102159\">",
"    <span class=\"h2\">",
"     Replication capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Replication capacity refers to the ability of the virus to replicate. Replication capacity can either decrease or increase in the setting of certain mutations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/48/4873?source=see_link\">",
"     \"Overview of HIV drug resistance testing assays\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the early era of potent ART, some patients demonstrated transient immunologic benefit despite ongoing viremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This may have been related to the selection of a \"less fit\" drug-resistant virus population. Viral fitness is inferred through measurement of replication capacity, which can be obtained within the context of certain phenotypic assays (eg, PhenoSense HIV; Monogram Biosciences, Clinical Reference Laboratory).",
"   </p>",
"   <p>",
"    However, the primary goal is always complete viral suppression, which is associated with durable immunologic benefit. Viral suppression is usually achievable with currently available ARV medications, even among patients with multi-class drug resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27994?source=see_link&amp;anchor=H7365500#H7365500\">",
"     \"Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection\", section on 'Selecting a regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19102196\">",
"    <span class=\"h2\">",
"     Resistance selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an untreated HIV-infected patient, billions of virions are produced daily through viral replication, which is an error-prone process. Viruses with spontaneous mutations are often defective and might not replicate. However, some mutations can persist in resting memory cells if the mutant virus has a selective growth advantage over wild-type virus.",
"   </p>",
"   <p>",
"    Drug resistant mutations can pre-date the onset of a specific drug regimen. These mutations may be related to transmission of a drug-resistant virus at the time of initial infection, or may arise due to incomplete adherence during drug exposure. When treatment is initiated, resistant virions have a replicative advantage over \"wild-type\" HIV. In the presence of a nonsuppressive ART regimen, the resistant mutants become the predominant strain and replace wild-type virus.",
"   </p>",
"   <p>",
"    The presence of drug resistance may be less evident in a patient who is no longer taking ART, since the wild-type HIV strain may become dominant again. Furthermore, current resistance assays may not detect certain drug resistance mutations that are present at low frequency (eg, less than about 20 percent of the viral population) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/8\">",
"     8",
"    </a>",
"    ]. If drug resistance testing is performed in the absence of drug pressure, test results can be misleading by suggesting drug susceptibility. Thus, it is important to obtain resistance testing in the presence of ART when possible, or within weeks of discontinuation, to fully assess any evidence of resistance mutations. In addition, these limitations of drug resistance testing also emphasize the importance of taking a complete medication history. (See",
"    <a class=\"local\" href=\"#H19101617\">",
"     'General principles'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, if resistance testing is performed off ART, any identified mutations would be of significance, since some studies have demonstrated that certain substitutions may persist off ART, even for years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/48/4873?source=see_link\">",
"     \"Overview of HIV drug resistance testing assays\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19102011\">",
"    <span class=\"h2\">",
"     Mutational patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;When trying to interpret resistance test results, it is important to understand the terminology used. By convention, mutations are indicated by a codon number preceded by a letter indicating the consensus amino acid in wild-type (drug-susceptible) virus and followed by a letter indicating the amino acid substitution in the mutant virus. For example, M184V would indicate that valine has been substituted for methionine at amino acid codon 184 in the reverse transcriptase enzyme. The notation",
"    <span class=\"nowrap\">",
"     M184M/V",
"    </span>",
"    indicates the presence of a mixture of wild-type (M) and mutant (V) virus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Signature mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A &ldquo;signature mutation&rdquo; is a mutation that is typically associated with resistance to a particular drug. For example, I50L is the signature mutation for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    , a protease inhibitor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cross-resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;cross-resistance&rdquo; refers to resistance to drugs other than the drug that selected the mutation(s). For example, the M184V mutation associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    confers cross-resistance to the related drug,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    . Furthermore, certain mutations selected by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    may lead to cross-resistance to all other nucleoside analog reverse transcriptase inhibitors (NRTIs).",
"   </p>",
"   <p>",
"    In some circumstances, cross-resistance to one drug may confer resistance to most, if not all drugs, in a class. For example, the K103N mutation confers resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    . However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    remains active against virus expressing K103N. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Non-nucleoside reverse transcriptase inhibitors (NNRTIs)'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9287?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hypersusceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some mutations can increase susceptibility to other drugs. For example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistant virus is often hypersusceptible to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    compared to wild-type virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Accessory mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;When HIV continues to replicate, additional minor mutations may accumulate over time. These accessory or secondary mutations can lead to increased viral fitness or drug resistance. Thus, it is important to switch ART rather than exposing a patient with ongoing viremia to the same drugs, which can lead to accessory mutations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36265?source=see_link\">",
"     \"Modifying HIV antiretroviral therapy regimens\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Genetic barrier to resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetic barrier to resistance is defined as &ldquo;low&rdquo; when a single mutation causes high-level resistance. In contrast, the genetic barrier to resistance is considered &ldquo;high&rdquo; when multiple mutations are needed to significantly reduce susceptibility to a drug.",
"   </p>",
"   <p>",
"    For example, the K103N mutation alone causes high-level resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , whereas multiple mutations are required to significantly decrease the activity of many protease inhibitors (PIs). In general,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted protease inhibitors have the highest genetic barrier to drug resistance, while unboosted protease inhibitors, integrase inhibitors, nucleoside reverse transcriptase inhibitors and some nucleoside reverse transcriptase inhibitors have a low genetic barrier. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Protease inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It is important to separate concepts of the &ldquo;genetic barrier of resistance&rdquo; from the overall efficacy of an ART regimen. A regimen consisting of several agents with low barriers to resistance may be highly effective and durable. For example, the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , and either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    has become a \"gold-standard\" regimen, even though resistance to each component of the regimen can be mediated by a single mutation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2899363\">",
"    <span class=\"h2\">",
"     Pharmacokinetic boosting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;pharmacokinetic boosting&rdquo; is often used in the context of protease inhibitor therapy.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     Ritonavir",
"    </a>",
"    is a potent inhibitor of hepatic microsomal isoenzyme CYP (450) 3A4. This characteristic is used beneficially when ritonavir is used to \"boost\" the serum concentration of other PIs. Use of pharmacokinetic boosting improves serum trough concentrations and decreases the risk of breakthrough viremia and drug resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/11\">",
"     11",
"    </a>",
"    ]. All PIs except",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    have received FDA approval for use with pharmacokinetic boosting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=see_link&amp;anchor=H32#H32\">",
"     \"HIV protease inhibitors\", section on 'Pharmacokinetic boosting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In clinical practice, the use of pharmacokinetic boosting is recommended in all patients taking PIs who can tolerate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    . While studies involving",
"    <span class=\"nowrap\">",
"     lopinavir/ritonavir",
"    </span>",
"    were the first to demonstrate very low rates of PI resistance in treatment-naive patients, there are now similar data for essentially all ritonavir-boosted PIs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any nucleoside reverse transcriptase inhibitor (NRTI) can select for resistance mutations when used in a nonsuppressive regimen (",
"    <a class=\"graphic graphic_table graphicRef69695 \" href=\"mobipreview.htm?33/17/34075\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef66938 \" href=\"mobipreview.htm?16/11/16569\">",
"     figure 1",
"    </a>",
"    ). The specific mutation pattern selected may be associated with varying degrees of NRTI cross-resistance. In general, a single mutation can lead to high-grade resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    , whereas resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    usually requires multiple mutations. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Genetic barrier to resistance'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Zidovudine and stavudine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    are thymidine analogs, which share common resistance patterns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Common resistance mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common resistance mutations include M41L, L210W, T215Y, D67N, K70R, and",
"    <span class=\"nowrap\">",
"     K219Q/E/N",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/12\">",
"     12",
"    </a>",
"    ]. These substitutions are referred to as \"thymidine analog mutations\" (TAMs) because they are selected by the two thymidine analogs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    ). Regimens containing a thymidine analog can select for TAMs and additional mutations, including",
"    <span class=\"nowrap\">",
"     44D/A,",
"    </span>",
"    118I,",
"    <span class=\"nowrap\">",
"     207D/E,",
"    </span>",
"    208Y.",
"   </p>",
"   <p>",
"    TAMs typically emerge via one of two \"pathways\":",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pattern 1 includes the M41L, L210W and T215Y mutations",
"     </li>",
"     <li>",
"      Pattern 2 involves the D67N, K70R, and",
"      <span class=\"nowrap\">",
"       K219Q/E/N",
"      </span>",
"      mutations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there can be mixtures of both patterns present in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. TAMs continue to accumulate when patients continue failing ART regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    are no longer considered preferred agents in resource-rich settings because of associated drug toxicities. However, it is still important to understand their effect on drug resistance among patients who were previously exposed to these agents. Zidovudine also continues to be used extensively in resource-limited settings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/34/10794?source=see_link\">",
"     \"Adverse effects of antiretroviral therapy in developing countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The first TAM pathway listed above confers cross-resistance to all NRTIs and the nucleotide analog,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The second pathway confers resistance primarily to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    , but causes less cross-resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    , and tenofovir. Since zidovudine and stavudine are both thymidine analogs, resistance to zidovudine typically results in cross-resistance to stavudine, and vice versa.",
"   </p>",
"   <p>",
"    TAMs are uncommon with early failure of a thymidine analog-containing regimen. At least three TAMs are usually required before virologic activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    is completely lost. However, continuation of a thymidine analog-containing regimen in the presence of ongoing viremia will result in accumulation of additional TAMs, leading to greater resistance and NRTI cross-resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the case of multiple TAMs, phenotypic testing may be helpful for determining whether any NRTIs are likely to have partial activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/20\">",
"     20",
"    </a>",
"    ]. However, the use of fully active agents is preferred whenever feasible; extensive NRTI resistance may lead to selection of an ART regimen that includes agents from alternative drug classes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27994?source=see_link&amp;anchor=H7365325#H7365325\">",
"     \"Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection\", section on 'Resistance to nucleoside reverse transcriptase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Lamivudine and emtricitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    are NRTIs with a low genetic barrier to resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Common resistance mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    both select for the M184V mutation, which is the most prevalent NRTI-associated mutation seen in treated patients (given their widespread use) and is often the first mutation to appear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/20\">",
"     20",
"    </a>",
"    ]. Some studies have suggested that the risk of developing the M184V mutation may be lower in patients prescribed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    compared with those on the combination of lamivudine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;M184V (as well as the less common M184I) mutation causes high-level resistance to both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    . It also causes a modest decrease in susceptibility to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/23\">",
"     23",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, M184V confers hypersusceptibility to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    and thus partially reverses TAM-mediated resistance to these drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/17\">",
"     17",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H11\">",
"     'Hypersusceptibility'",
"    </a>",
"    above). It also leads to decreased replication capacity of HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, a viral isolate with this mutation is \"less fit\" than wild-type virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/26\">",
"     26",
"    </a>",
"    ]. Continuation of either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    , with maintenance of the M184V mutation, leads to a persistent mean 0.5 log decrease in viral load from baseline compared to increasing viremia when this drug is stopped. (See",
"    <a class=\"local\" href=\"#H19102159\">",
"     'Replication capacity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In the past, maintaining",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    despite the presence of this mutation was a common practice based on the excellent tolerability, residual partial virologic activity, and the beneficial effect on susceptibility to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/27\">",
"     27",
"    </a>",
"    ]. However, in light of the overall success in attaining viral suppression with potent later generation antiretroviral medications (even among treatment-experienced patients), the need for such an approach has lessened over the past decade. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27994?source=see_link\">",
"     \"Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Tenofovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    is a nucleotide reverse transcriptase inhibitor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Common resistance mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;K65R is the signature mutation associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/28\">",
"     28",
"    </a>",
"    ]. It is also infrequently selected by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    . A less common mutation associated with tenofovir exposure is K70E [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/29\">",
"     29",
"    </a>",
"    ]. Some thymidine analog mutations (specifically M41L, L210W, and T215Y) also confer resistance to tenofovir.",
"   </p>",
"   <p>",
"    The emergence of the K65R mutation may be influenced by the underlying immune status of the host and by the use of other agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial (GS 903) compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      in 602 treatment-naive patients who also received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/30\">",
"       30",
"      </a>",
"      ]. The K65R mutation emerged in about 21 percent of the tenofovir-treated participants who did not achieve complete virologic suppression; most of these patients had a low pretreatment CD4 count and a high viral load.",
"     </li>",
"     <li>",
"      However, in a study comparing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      -based therapy (ie, GS 934), the K65R mutation did not emerge in tenofovir-treated patients, possibly because of the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      instead of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/31\">",
"       31",
"      </a>",
"      ]. Emtricitabine has a better overall pharmacokinetic profile than lamivudine, which may have contributed to overall efficacy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41209?source=see_link\">",
"       \"Pharmacology of nucleoside reverse transcriptase inhibitors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The K65R mutation is associated with certain benefits and disadvantages. K65R confers significant cross-resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/34\">",
"     34",
"    </a>",
"    ]. However, like the M184V mutation, the K65R mutation is associated with a significant decrease in HIV replication capacity, which may be additive when M184V is also present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/25\">",
"     25",
"    </a>",
"    ]. Fortunately, the overall prevalence of the K65R mutation is low and thus,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    is usually a potent NRTI in most ART regimens. (See",
"    <a class=\"local\" href=\"#H19102159\">",
"     'Replication capacity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Furthermore, K65R induces hypersusceptibility to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/8\">",
"     8",
"    </a>",
"    ], similar to that seen with the M184V mutation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Abacavir and didanosine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     Abacavir",
"    </a>",
"    is commonly used, while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    is rarely used today because of its associated adverse events, including mitochondrial toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/40/30345?source=see_link\">",
"     \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Common resistance mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The common mutation for both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    is L74V, which confers resistance to both drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Less commonly, abacavir also selects for other mutations, including K65R, Y115F and M184V.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;When L74V is present in combination with M184V, there is further loss of susceptibility to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    . However, the presence of both mutations increases susceptibility to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, L74V mutant isolates are less fit than wild-type virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Multinucleoside resistance mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the most common cause of broad NRTI cross-resistance is multiple TAMs with M184V [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/17\">",
"     17",
"    </a>",
"    ], two other resistance patterns can also lead to significant NRTI cross resistance:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Q151M complex is associated with resistance to all NRTIs except",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The T69 insertion mutation causes resistance to all NRTIs, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      , when this mutation is accompanied by one or more TAMs at codons 41, 210, or 215.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These mutations are usually selected by NRTI backbones that include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    . Fortunately, these multinucleoside resistance mutations are relatively uncommon in current clinical practice since these combinations are rarely used. If these mutations are present, the clinician may consider using three classes of antiretroviral medications, which do not include NRTIs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27994?source=see_link\">",
"     \"Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the &ldquo;first generation&rdquo; of agents within the NNRTI class (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ) has a &ldquo;low genetic barrier&rdquo; to resistance compared with the protease inhibitor class. There is also significant cross-resistance between efavirenz and nevirapine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/15\">",
"     15",
"    </a>",
"    ]. As a result, selection of a single point mutation (eg, K103N) usually confers loss of drug activity to both of these NNRTIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/38\">",
"     38",
"    </a>",
"    ]. Despite this low barrier to resistance, efavirenz and nevirapine are generally effective in attaining viral suppression (among patients without preexisting NNRTI drug resistance) due to their intrinsic potency and long half-lives.",
"   </p>",
"   <p>",
"    Newer generation NNRTI agents include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    . There are scant data regarding resistance mutations selected by etravirine in wild-type strains, since this drug has not been studied extensively in treatment-naive patients. In contrast, there are extensive drug resistance data on rilpivirine, which has been studied only in treatment-naive patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Below is a summary of specific mutations associated with each drug in the NNRTI class and the potential impact of these mutations on treatment strategies (",
"    <a class=\"graphic graphic_figure graphicRef66938 \" href=\"mobipreview.htm?16/11/16569\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Common mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common mutations seen in association with &ldquo;first generation&rdquo; NNRTIs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ) are K103N and Y181C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/42\">",
"     42",
"    </a>",
"    ]. K103N is selected by efavirenz more frequently than by nevirapine; Y181C is selected more commonly by nevirapine when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    is not coadministered. These NNRTIs may also select Y188L, which confers high-level resistance to approved NNRTIs when present as a single mutation. Other common mutations selected by efavirenz and nevirapine include: L100I, V106A,",
"    <span class=\"nowrap\">",
"     G190S/A,",
"    </span>",
"    and M230L.",
"   </p>",
"   <p>",
"    In clinical trials that have evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    in treatment-naive patients, virologic failure was associated with the emergence of the following resistance-associated mutations: K101E, V189I, Y181C, V90I, H221Y and E138K, the most frequently observed mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. E138K is a novel NNRTI mutation that alone leads to high-level rilpivirine resistance.&nbsp;This mutation also confers cross-resistance to the other NNRTIs, though the degree of cross-resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    is variable.&nbsp;In studies where rilpivirine was given with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , the E138K mutation was most often seen in association with the NRTI mutation M184I, or less commonly, with M184V [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/40,41,43\">",
"     40,41,43",
"    </a>",
"    ]. As noted above,",
"    <span class=\"nowrap\">",
"     M184I/V",
"    </span>",
"    mutations are associated with a decline in replication capacity, but the coexistence of the E138K mutation appears to restore viral fitness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/43\">",
"     43",
"    </a>",
"    ], particularly when found in combination with M184I [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     Etravirine",
"    </a>",
"    is a second generation NNRTI with activity against a large proportion of NNRTI-resistant viruses isolated from patients with virologic failure on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    . The K103N mutation, which is the most common mutation to emerge with efavirenz failure, does not lead to cross-resistance to etravirine. Retrospective analyses from the DUET trials of etravirine efficacy have identified 17 mutations that may diminish response to etravirine, including V90I, A98G, L100I,",
"    <span class=\"nowrap\">",
"     K101E/P,",
"    </span>",
"    V106I,",
"    <span class=\"nowrap\">",
"     V179D/F,",
"    </span>",
"    <span class=\"nowrap\">",
"     Y181C/I/V/Y,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     G190S/A",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/45\">",
"     45",
"    </a>",
"    ]. In general, an increasing number of mutations have been correlated with declining treatment responses, but no single mutation has led to high-level resistance to etravirine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/45\">",
"     45",
"    </a>",
"    ]. However, some mutations, most notably at codon 181, can lead to \"intermediate\" level resistance and appear to have a significant negative impact on etravirine susceptibility and activity (",
"    <a class=\"graphic graphic_table graphicRef55515 \" href=\"mobipreview.htm?37/19/38204\">",
"     table 2",
"    </a>",
"    ). There are no clinical data on the use of etravirine after virologic failure on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emergence of K103N confers broad resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    . Accumulation of two or more common mutations (eg, L100I, V106A, Y181C,",
"    <span class=\"nowrap\">",
"     G190S/A,",
"    </span>",
"    and M230L) is also associated with broad class resistance.",
"   </p>",
"   <p>",
"    Initial NNRTI resistance mutations tend to emerge quickly in patients with detectable viremia during NNRTI-based therapy. Maintaining NNRTI therapy in viremic patients on either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    risks accumulation of further NNRTI resistance mutations, which may reduce the utility of other agents in this class (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    ). In addition, there is no other benefit to continued use of these drugs, since most common NNRTI resistance mutations have little effect on viral fitness, and these drugs have minimal, if any, antiviral activity in the presence of these mutations. Therefore, first-generation NNRTIs should be discontinued in patients experiencing virologic failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27994?source=see_link\">",
"     \"Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Even though",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    may appear phenotypically active in the presence of Y181C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/38\">",
"     38",
"    </a>",
"    ], studies have shown that a strategy of using efavirenz following the development of the Y181C mutation on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    leads to the rapid development of resistance and virologic failure; thus, this strategy should be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     Etravirine",
"    </a>",
"    retains potency against a large percentage of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    - and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    -resistant clinical isolates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/48\">",
"     48",
"    </a>",
"    ]. Specifically, an isolated K103N mutation does not confer resistance to etravirine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/48\">",
"     48",
"    </a>",
"    ]. However, the presence of other NNRTI-associated mutations may affect etravirine potency, as noted above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/45\">",
"     45",
"    </a>",
"    ]. Phenotypic drug resistance testing is helpful in determining the residual activity of etravirine when multiple mutations are found on genotypic testing.",
"   </p>",
"   <p>",
"    Isolated mutations associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    exposure, such as E138K, appear to confer some degree of cross resistance to the other NNRTIs, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. There are no clinical data on the use of another NNRTI (including etravirine) after virologic failure on rilpivirine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Hypersusceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence for enhanced activity of one or more of the NNRTIs in the presence of multiple TAMs and some other NRTI resistance mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. In some studies, NNRTI \"hypersusceptibility\" was associated with improved outcomes when an NNRTI was incorporated into a subsequent regimen after the development of NRTI resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/53\">",
"     53",
"    </a>",
"    ]. However, the clinical utility of this observation is unclear, since thymidine analogs are much less frequently used as part of initial therapy, TAMs are becoming less common, and NNRTIs are frequently used for initial therapy in patients with wild-type virus based on their efficacy, tolerability, and low rates of long-term toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     PROTEASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most protease inhibitors (PIs), especially those given in combination with low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    , have a &ldquo;high genetic barrier&rdquo; to resistance; thus, decreased drug susceptibility generally requires an accumulation of multiple mutations (",
"    <a class=\"graphic graphic_figure graphicRef79835 \" href=\"mobipreview.htm?3/60/4039\">",
"     figure 2",
"    </a>",
"    ). When ritonavir-boosted PIs are used by patients without pre-existing PI resistance, treatment failure is rarely associated with PI resistance, as discussed below. Ritonavir boosting is used to increase serum trough concentrations of the parent drug. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=see_link&amp;anchor=H32#H32\">",
"     \"HIV protease inhibitors\", section on 'Pharmacokinetic boosting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PI-associated mutations are classified as either primary (major) or secondary (minor) mutations. The mutations that emerge will depend on which medication is being administered. However, it should be emphasized that most data on mutations associated with failure of PI-based regimens come from studies of unboosted PIs, which are rarely used today.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Cross-resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common mutations that are shared by two or more drugs confer cross-resistance. For example, the presence of at least two key mutations (eg,",
"    <span class=\"nowrap\">",
"     V82A/F/T/S,",
"    </span>",
"    I84V, and L90M) can confer broad cross-resistance to earlier generation PIs, which are rarely used today (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    ). The use of unboosted amprenavir or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"     fosamprenavir",
"    </a>",
"    can lead to cross-resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Common mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common, as well as unique mutations for individual PIs, are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Atazanavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signature mutation associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    resistance is I50L, which does not decrease susceptibility to other PIs, and in some cases may lead to hypersusceptibility to these drugs. Other potential mutations include I84V and N88S.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15740146\">",
"    <span class=\"h3\">",
"     Darunavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     Darunavir",
"    </a>",
"    maintains virologic activity despite multiple PI mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/54\">",
"     54",
"    </a>",
"    ]. In a pooled subset analysis of clinical trials comparing darunavir to optimized ART in highly treatment-experienced patients, the effect of baseline susceptibility on treatment efficacy was examined. Forty-seven percent of patients treated with darunavir, who had multiple mutations at baseline, still attained viral suppression. Furthermore, one prevalence study of more than 90,000 viral isolates from treatment-experienced patients demonstrated that the co-existence of three or more darunavir resistance mutations was seen at the pretreatment baseline in only 7 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/55\">",
"     55",
"    </a>",
"    ]. For this reason, darunavir is an important agent for use in treatment-experienced patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=see_link&amp;anchor=H44#H44\">",
"     \"HIV protease inhibitors\", section on 'Darunavir'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mutations that alter the virologic response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    include: 11I, V32I, L33F, I47V, I50V,",
"    <span class=\"nowrap\">",
"     I54L/M,",
"    </span>",
"    G73S, L76V, I84V, L89V. Interpreting complex genotypes can be challenging in patients with multiple PI resistance mutations. In such cases, phenotypic resistance testing may offer an advantage over genotypic testing as it measures resistance more directly and can assess relative susceptibility and interactions among mutations. When using phenotypic assays, an optimal response to darunavir is associated with a phenotypic fold change &le;10 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     Darunavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    , two PIs commonly used in treatment-experienced patients, have distinct drug resistance profiles. Mutations I50V, I54L, and L76V confer significant resistance to darunavir, but hypersusceptibility to tipranavir in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast, previous tipranavir treatment failure does not appear to undermine the efficacy of DRV for salvage therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15740245\">",
"    <span class=\"h3\">",
"     Fosamprenavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common mutations associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"     fosamprenavir",
"    </a>",
"    use include I50V and I84V. These mutations are also associated with cross-resistance to other PIs, most notably",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Indinavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common mutations associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    resistance include",
"    <span class=\"nowrap\">",
"     M46/I/L,",
"    </span>",
"    <span class=\"nowrap\">",
"     V82A/F/T,",
"    </span>",
"    or I84V. The latter two mutations are also selected by other PIs and have a significant impact on most other PIs. This drug is no longer considered a first-line drug for the treatment of HIV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Lopinavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lopinavir is only available in a coformulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    . Several PI mutations are required before its efficacy is significantly compromised [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/58\">",
"     58",
"    </a>",
"    ]. Key mutations include V32I,",
"    <span class=\"nowrap\">",
"     I47V/A,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     V82A/F/T/S.",
"    </span>",
"    Another primary lopinavir resistance mutation is L76V, which sensitizes viral strains to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For many years, the use of lopinavir was the standard of care for patients who had some degree of resistance as a result of the use of any of the previously mentioned PIs. However, in patients with extensive PI resistance,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    are now preferred over early generation PIs, since these agents have greater activity against PI-resistant virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/54,60\">",
"     54,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27994?source=see_link&amp;anchor=H7365402#H7365402\">",
"     \"Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection\", section on 'Resistance to protease inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15740282\">",
"    <span class=\"h3\">",
"     Nelfinavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signature mutation associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    resistance is the D30N mutation, which does not affect susceptibility to other PIs. Another less common mutation associated with nelfinavir use is L90M, which causes cross-resistance to other PIs. This drug is sometimes used in pregnant HIV-infected women. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Cross-resistance'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15740260\">",
"    <span class=\"h3\">",
"     Saquinavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common mutations associated with emergence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    resistance include the unique G48V mutation as well as the L90M mutation, which is associated with PI cross-resistance. This drug is no longer considered a first-line drug for the treatment of HIV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Tipranavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"     Tipranavir",
"    </a>",
"    also has a unique resistance profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Analysis of a comprehensive data set obtained from heavily treatment-experienced patients in the RESIST trials identified mutations at 16 codons that were associated with decreased susceptibility to tipranavir: 10V, 13V,",
"    <span class=\"nowrap\">",
"     20M/R/V,",
"    </span>",
"    33F, 35G, 36I, 43T, 46L, 47V,",
"    <span class=\"nowrap\">",
"     54A/M/V,",
"    </span>",
"    58E, 69K, 74P,",
"    <span class=\"nowrap\">",
"     82L/T,",
"    </span>",
"    83D, 84V. A \"weighted tipranavir mutation score\" was subsequently developed for predicting susceptibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/63\">",
"     63",
"    </a>",
"    ]. A score of &lt;3 indicates susceptibility, &gt;3 but &lt;10 partial susceptibility, and &gt;11 resistance. &nbsp;Mutations which confer increased susceptibility are weighted on a negative scale, while those which confer increased resistance are weighted on a positive scale. The specific mutations and their weighted scores are listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      74P,",
"      <span class=\"nowrap\">",
"       82L/T,",
"      </span>",
"      83D, 47V: (+4)",
"     </li>",
"     <li>",
"      58E and 84V: (+3)",
"     </li>",
"     <li>",
"      36I, 43T, and",
"      <span class=\"nowrap\">",
"       54A/M/V:",
"      </span>",
"      (+2)",
"     </li>",
"     <li>",
"      10V, 33F and 46L: (+1)",
"     </li>",
"     <li>",
"      24I and 76V: (-2)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       50L/V:",
"      </span>",
"      (-4)",
"     </li>",
"     <li>",
"      54L: (-6)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Use of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    mutation score can be helpful in determining this agent's use in a heavily treatment-experienced patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H392453\">",
"    <span class=\"h2\">",
"     Implications for use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preferred first-line protease inhibitors for the management of treatment-naive HIV-infected patients include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    based on potency and adverse effect profile. Prior to initiation of treatment, drug resistance testing should be performed to rule out baseline mutations, which may affect antiviral efficacy.",
"   </p>",
"   <p>",
"    Among treatment-experienced patients with known or suspected drug resistance,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    is favored over other HIV protease inhibitors (if the drug resistance profile is supportive of darunavir efficacy). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27994?source=see_link&amp;anchor=H7365325#H7365325\">",
"     \"Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection\", section on 'Resistance to nucleoside reverse transcriptase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pharmacokinetic boosting of HIV protease inhibitors with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    is generally recommended to decrease the emergence of drug resistance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=see_link&amp;anchor=H32#H32\">",
"     \"HIV protease inhibitors\", section on 'Pharmacokinetic boosting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     FUSION INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    is a result of mutations occurring in a critical sequence of 10 amino acids (aa 36-45) within the helical region (HR-1) of gp-41 envelope (env) gene, and to a lesser extent in other areas of the envelope gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/64\">",
"     64",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_figure graphicRef76114 \" href=\"mobipreview.htm?36/61/37841\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1263082\">",
"    <span class=\"h2\">",
"     Common mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The substitutions most frequently associated with resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    include:",
"    <span class=\"nowrap\">",
"     G36D/S/V/E,",
"    </span>",
"    <span class=\"nowrap\">",
"     V38A/E/M,",
"    </span>",
"    Q40H, N42T, and N43D [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H392619\">",
"    <span class=\"h2\">",
"     Implications for use",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7205?source=see_link\">",
"     Enfuvirtide",
"    </a>",
"    was an important component of ART among patients with multidrug resistance with limited treatment options [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/65\">",
"     65",
"    </a>",
"    ], although it is now infrequently used because of the availability of other orally administered agents. The genetic barrier to resistance to enfuvirtide is low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/66\">",
"     66",
"    </a>",
"    ], which emphasizes the importance of administering enfuvirtide with other active agents, whenever feasible.",
"   </p>",
"   <p>",
"    Genotypic assays for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    resistance are commercially available. However, there are few data to guide practitioners as to whether enfuvirtide has residual activity based on these resistance mutation patterns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/4,67\">",
"     4,67",
"    </a>",
"    ]. Thus, it is practical to expect maximal activity with enfuvirtide when it is used for the first time; in contrast, there is likely to be minimal, if any, antiviral activity if this drug was previously utilized in a nonsuppressive regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h1\">",
"     CCR5 ANTAGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another class of entry inhibitors are the CCR5 antagonists. In addition to attachment to the CD4 receptor, HIV entry requires binding to coreceptor molecules, CCR5 or CXCR4, to enter CD4 cells. Viruses that enter the cell by binding to the CCR5 coreceptor are referred to as R5 viruses; those that utilize CXCR4 are X4 viruses; and those that can use either receptor or that are part of a mixed R5 and X4 population are collectively referred to as",
"    <span class=\"nowrap\">",
"     dual/mixed",
"    </span>",
"    <span class=\"nowrap\">",
"     (D/M)",
"    </span>",
"    viruses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/39/24186?source=see_link&amp;anchor=H12#H12\">",
"     \"Factors affecting HIV progression\", section on 'Coreceptor usage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1263089\">",
"    <span class=\"h2\">",
"     Tropism testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because CCR5 antagonists are not active against X4 or",
"    <span class=\"nowrap\">",
"     D/M",
"    </span>",
"    viruses, a pretreatment screening test must be utilized to assess viral tropism. This tropism test (Trofile ES&reg;) is similar to an HIV resistance phenotype, and is highly sensitive for detecting X4 or",
"    <span class=\"nowrap\">",
"     D/M",
"    </span>",
"    virus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/48/4873?source=see_link\">",
"     \"Overview of HIV drug resistance testing assays\"",
"    </a>",
"    .) A newer assay, Trofile DNA&reg;, can be used to determine tropism in patients with suppressed viral loads, although it has not been clinically validated or FDA approved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Maraviroc",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/45/20182?source=see_link\">",
"     Maraviroc",
"    </a>",
"    is a selective and reversible CCR5 coreceptor antagonist with a wide range of activity against clinical HIV isolates, including those with multi-drug resistance.",
"   </p>",
"   <p>",
"    In clinical trials, virologic failure of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    has been attributed to the emergence of X4 viruses. The primary mechanism for this phenomenon appears to be selection of pre-existing minority populations that were not detectable at baseline due to extreme diversity of the viral subpopulations in treatment-experienced patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/68\">",
"     68",
"    </a>",
"    ]. This may become a less common cause of failure than it was in early studies because of the improved sensitivity of the tropism assay at detecting X4 or",
"    <span class=\"nowrap\">",
"     D/M",
"    </span>",
"    virus, but even the enhanced sensitivity assay can miss low frequency variants which emerge under nonsuppressive treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment failure can also occur as a result of emergence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    resistance mutations in R5 tropic virus, but this process not been well characterized to date, and resistance testing is not yet commercially available (",
"    <a class=\"graphic graphic_figure graphicRef76114 \" href=\"mobipreview.htm?36/61/37841\">",
"     figure 3",
"    </a>",
"    ). Phenotypically, resistance to CCR5 receptor antagonists manifests not as a rightward shift of the IC",
"    <sub>",
"     50",
"    </sub>",
"    curve, but as a plateau in the maximum achievable suppression of viral replication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/2\">",
"     2",
"    </a>",
"    ]. This plateau correlates with the ability of HIV to adapt to the inhibitor-bound form of CCR5 for entry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H392645\">",
"    <span class=\"h2\">",
"     Implications for use",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/45/20182?source=see_link\">",
"     Maraviroc",
"    </a>",
"    is approved for HIV therapy in treatment-naive and treatment-experienced patients. Prior to administration of maraviroc, a tropism test must be performed to rule out the presence of X4 or",
"    <span class=\"nowrap\">",
"     D/M",
"    </span>",
"    viruses since maraviroc is not active against these viruses. The clinical use of maraviroc is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27994?source=see_link&amp;anchor=H7365458#H7365458\">",
"     \"Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection\", section on 'Resistance to CCR5 antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h1\">",
"     INTEGRASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-1 integrase is essential for viral replication; integrase inserts viral DNA into the cellular genome through two catalytic reactions. Loss of integrase activity disrupts the viral life cycle (",
"    <a class=\"graphic graphic_figure graphicRef54130 \" href=\"mobipreview.htm?1/33/1553\">",
"     figure 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/34/7720?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Raltegravir and elvitegravir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    and elvitegravir are integrase inhibitors with potent in vitro activity against both wild-type and multidrug-resistant HIV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1263096\">",
"    <span class=\"h2\">",
"     Common mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signature mutations in the integrase gene associated with resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    include",
"    <span class=\"nowrap\">",
"     Q148H/K/R,",
"    </span>",
"    Y143C and N155H, which develop along three key resistance pathways. Mutations at codon 148 are associated with the highest level of raltegravir resistance, and become more prevalent with ongoing failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/71\">",
"     71",
"    </a>",
"    ]. In a longitudinal analysis of a phase II study, there was a trend for the N155H mutation to be replaced by the Q148H mutation, which became predominant over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/72\">",
"     72",
"    </a>",
"    ]. These data suggest that viruses with the Q148H mutation, in combination with other secondary mutations, have greater replicative fitness in vitro than virus with the N155H mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary mutations for elvitegravir are Q148R, E92Q, and T66l. Additional mutations occur&nbsp;at codons 92,&nbsp;138, and 147 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A phenotypic test to assess",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    resistance is commercially available (Monogram Biosciences). Genotypic resistance tests are also available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/76\">",
"     76",
"    </a>",
"    ], are generally preferred, since they provide data that are useful for assessing not only susceptibility to currently available integrase inhibitors (raltegravir and elvitegravir), but also to investigational agents, such as dolutegravir. (see below).",
"   </p>",
"   <p>",
"    Dolutegravir, an investigational integrase inhibitor, is active against",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    - and elvitegravir-resistant virus with Y143C- or N155H-mediated resistance, but susceptibility is reduced in the presence of codon 148 mutations when other mutations are present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. However, when dosed twice daily, dolutegravir appears to have activity against virus with the 148 mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H392771\">",
"    <span class=\"h2\">",
"     Implications for use",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    is approved for use in the treatment-naive and treatment-experienced patient, while elvitegravir is approved for use in treatment-naive patients. Due to a different mechanism of action, there is no cross-resistance of raltegravir or elvitegravir with drugs from other classes.",
"   </p>",
"   <p>",
"    However, there is significant cross-resistance between these two members of the integrase inhibitor drug class, which is likely to preclude the use of elvitegravir after treatment failure on a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    -containing regimen and vice versa.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    is extremely effective in the treatment of heavily pretreated patients (as well as treatment-na&iuml;ve individuals). However, the use of raltegravir in a combination that does not include other active drugs is associated with the rapid loss of activity due to rapid emergence of resistance mutations. The emergence of drug resistance has been documented in some patients during episodes of low-level viremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following virologic failure, consideration should be given to stopping an integrase inhibitor to prevent the development of additional",
"    <span class=\"nowrap\">",
"     mutations/substitutions.",
"    </span>",
"    An integrase genotype should be obtained before or at the time of discontinuation, as the result may help determine the likelihood of activity of investigational agents, such as dolutegravir. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27994?source=see_link&amp;anchor=H7365479#H7365479\">",
"     \"Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection\", section on 'Resistance to integrase strand transfer inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link&amp;anchor=H27#H27\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\", section on 'Integrase strand transfer inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complex mutational patterns can be difficult to interpret. Multiple web sites are available that contain comprehensive summaries of HIV-1 drug resistance mutations that are helpful to clinicians. Three of the web sites are listed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/26/34218/abstract/81\">",
"     81",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The International AIDS Society-USA drug resistance mutation site is maintained by a group of experts that updates its summary biannually (",
"      <a class=\"external\" href=\"file://www.iasusa.org/resistance_mutations/mutations_figures.pdf\">",
"       file://www.iasusa.org/resistance_mutations/mutations_figures.pdf",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The HIV Sequence Database at Los Alamos National Laboratories maintains an updated review on approved and investigational agents (",
"      <a class=\"external\" href=\"file://resdb.lanl.gov/Resist_DB/default.htm\">",
"       file://resdb.lanl.gov/Resist_DB/default.htm",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The Drug Resistance Summary section of the Stanford University HIV Drug Resistance Database contains diagrammatic summaries of mutations by drug class, and provides interpretation of specific genotypes that are input by the user (",
"      <a class=\"external\" href=\"file://hivdb.stanford.edu/\">",
"       file://hivdb.stanford.edu/",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The onset of drug resistance leads to viral rebound and eventual loss of immunologic benefit. Accumulation of additional mutations in the face of ineffective therapy further compromises treatment options. Understanding the implications of the resistance patterns for specific medications and drug classes is important for optimal patient management. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The best way to avoid the onset of drug resistance is to maintain viral suppression, defined as a viral load below the detection limit on an ultrasensitive viral load assay. Drug resistance occurs when viral replication continues in the face of ongoing drug pressure. (See",
"      <a class=\"local\" href=\"#H19101617\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At the time of diagnosis, drug resistance testing should be performed to guide selection of antiretroviral therapy (ART). Genotypic testing is preferred in the treatment-naive patient or in the patient who requires a first modification of ART due to virologic failure. Patients with an extensive history of virologic failure may benefit from additional phenotypic drug resistance testing. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of resistance testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The genetic barrier to resistance may be considered &ldquo;low&rdquo; when a single mutation, causing high-level resistance, emerges quickly at the time of virologic failure. In contrast, the genetic barrier to resistance is considered &ldquo;high&rdquo; when multiple mutations are needed to significantly reduce susceptibility to a drug. However, it is important to distinguish between the genetic barrier of a single drug versus a multidrug regimen which can be very effective, even if each drug individually has a low genetic barrier to resistance. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Genetic barrier to resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The nonnucleoside reverse transcriptase inhibitors (NNRTIs)",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      share a low genetic barrier to resistance. With efavirenz and nevirapine, a single point mutation usually confers cross-resistance to both drugs.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"       Rilpivirine",
"      </a>",
"      also loses activity in the presence of a single mutation, E138K, which may confer cross-resistance to other NNRTIs. In contrast, no single mutation results in high-level resistance to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"       etravirine",
"      </a>",
"      , although there are some mutations (Y181C) that have a significant negative impact on susceptibility. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Non-nucleoside reverse transcriptase inhibitors (NNRTIs)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       Ritonavir",
"      </a>",
"      is generally given with protease inhibitors (PIs) to improve serum trough drug concentrations. Most ritonavir-boosted protease inhibitors have a high genetic barrier to resistance. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Protease inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The genetic barrier to resistance to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7205?source=see_link\">",
"       enfuvirtide",
"      </a>",
"      , a fusion inhibitor, is low. This medication may be helpful in constructing a regimen for a treatment-experienced patient with multidrug resistance. A history of prior exposure to enfuvirtide in the setting of ongoing viremia usually indicates enfuvirtide drug resistance. (See",
"      <a class=\"local\" href=\"#H45\">",
"       'Fusion inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The CCR5 antagonists (ie,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/45/20182?source=see_link\">",
"       maraviroc",
"      </a>",
"      ), are selective and reversible coreceptor antagonists with a wide range of activity against clinical HIV isolates, including those with multi-drug resistance. Maraviroc is only active against viruses which enter the cell using the CCR5 coreceptor. A tropism assay must be performed prior to use of maraviroc to determine whether the patient is infected with R5 virus; if not, maraviroc should not be used. (See",
"      <a class=\"local\" href=\"#H47\">",
"       'CCR5 antagonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Resistance to the integrase inhibitors,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      and elvitegravir, can occur as a result of single integrase mutation. They should only be used with two other potent agents to decrease the risk of drug resistance. The investigational integrase inhibitor, dolutegravir, may be active against raltegravir- and elvitegravir-resistant virus. (See",
"      <a class=\"local\" href=\"#H49\">",
"       'Integrase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/1\">",
"      Llibre JM, Schapiro JM, Clotet B. Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure. Clin Infect Dis 2010; 50:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/2\">",
"      Hirsch MS, G&uuml;nthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/3\">",
"      Li JZ, Paredes R, Ribaudo HJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011; 305:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/4\">",
"      Deeks SG, Lu J, Hoh R, et al. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis 2007; 195:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/5\">",
"      De Luca A, Weidler J, Di Giambenedetto S, et al. Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failure. J Acquir Immune Defic Syndr 2007; 45:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/6\">",
"      Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/7\">",
"      Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009; 49:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/8\">",
"      Underwood MR, Ross LL, Irlbeck DM, et al. Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1. J Infect Dis 2009; 199:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/9\">",
"      Smith DM, Wong JK, Shao H, et al. Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission. J Infect Dis 2007; 196:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/10\">",
"      Ross L, Parkin N, Chappey C, et al. Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance. AIDS 2004; 18:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/11\">",
"      Lima VD, Gill VS, Yip B, et al. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy. J Infect Dis 2008; 198:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/12\">",
"      Meyer PR, Matsuura SE, Schinazi RF, et al. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates. Antimicrob Agents Chemother 2000; 44:3465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/13\">",
"      Yahi N, Tamalet C, Tourr&egrave;s C, et al. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences. J Clin Microbiol 1999; 37:4099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/14\">",
"      Hanna GJ, Johnson VA, Kuritzkes DR, et al. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis 2000; 181:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/15\">",
"      D'Aquila RT, International AIDS Society-USA, Schapiro JM, et al. Drug Resistance Mutations in HIV-1. Top HIV Med 2002; 10:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/16\">",
"      Kuritzkes DR, Bassett RL, Young RK, et al. Rate of emergence of thymidine analogue resistance mutations in HIV-1 reverse transcriptase selected by stavudine or zidovudine-based regimens in treatment-na&iuml;ve patients. Antivir Ther 2002; 7:S31.",
"     </a>",
"    </li>",
"    <li>",
"     Whitcombe JM, Paxinos W, Huang M, et al. The Presence of Nucleoside Analogue Mutations (NAMs) is Highly Correlated with Reduced Suceptibility to all NRTIs. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, 24-28 February 2002. Abstract 569.",
"    </li>",
"    <li>",
"     Melby T. CNA3005: Detection of Mutations on Therapy in 3TC/ZDV+ABC Arm. 8th Conference on Retroviruses and Opportunistic Infections. February 4-8, 2001; Chicago, IL. Poster 448.",
"    </li>",
"    <li>",
"     Johnson V. 11th Conference on Retroviruses and Opportunistic Infections. February 8-11, 2004; San Francisco, CA. Poster 662.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/20\">",
"      Gallant JE. Antiretroviral drug resistance and resistance testing. Top HIV Med 2005; 13:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/21\">",
"      Maserati R, De Silvestri A, Uglietti A, et al. Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine. AIDS 2010; 24:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/22\">",
"      Svicher V, Alteri C, Artese A, et al. Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. J Acquir Immune Defic Syndr 2010; 55:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/23\">",
"      Walter H, Schmidt B, Werwein M, et al. Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivo. Antimicrob Agents Chemother 2002; 46:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/24\">",
"      Gallant JE, Gerondelis PZ, Wainberg MA, et al. Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antivir Ther 2003; 8:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/25\">",
"      Nicastri E, Sarmati L, d'Ettorre G, et al. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J Med Virol 2003; 69:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/26\">",
"      Eron JJ Jr. The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials. AIDS 1996; 10 Suppl 5:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/27\">",
"      Campbell TB, Shulman NS, Johnson SC, et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis 2005; 41:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/28\">",
"      Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999; 4:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/29\">",
"      Sluis-Cremer N, Sheen CW, Zelina S, et al. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2007; 51:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/30\">",
"      Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/31\">",
"      Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/32\">",
"      de Mendoza C, Jim&eacute;nez-Nacher I, Garrido C, et al. Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir. Clin Infect Dis 2008; 46:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/33\">",
"      von Wyl V, Yerly S, B&ouml;ni J, et al. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clin Infect Dis 2008; 46:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/34\">",
"      Miller MD. K65R, TAMs and tenofovir. AIDS Rev 2004; 6:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/35\">",
"      Wainberg MA, Turner D. Resistance issues with new nucleoside/nucleotide backbone options. J Acquir Immune Defic Syndr 2004; 37 Suppl 1:S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/36\">",
"      Wirden M, Lambert-Niclot S, Marcelin AG, et al. Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients. AIDS 2009; 23:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/37\">",
"      Sharma PL, Crumpacker CS. Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val. J Virol 1999; 73:8448.",
"     </a>",
"    </li>",
"    <li>",
"     Hellmann N, et al. 3rd International Workshop on HIV Drug Resistance and Treatment Strategies. June 23-26, 1999. San Diego, CA. Abstract 51.",
"    </li>",
"    <li>",
"     Stellbrink HJ, Rugina S, Zagler C, et al. The SENSE trial: etravirine shows lower prevalence and severity of neuropychiatric adverse events compared to efavirenz in treatment-naive patients. Tenth International Congress on Drug Therapy in HIV Infection. November 7-11, 2010. Glasgow. Abstract O431.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/40\">",
"      Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/41\">",
"      Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/42\">",
"      Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med 2011; 365:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/43\">",
"      Xu HT, Asahchop EL, Oliveira M, et al. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J Virol 2011; 85:11300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/44\">",
"      Hu Z, Kuritzkes DR. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J Virol 2011; 85:11309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/45\">",
"      Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 2010; 24:503.",
"     </a>",
"    </li>",
"    <li>",
"     Zaccarelli C, et al. 41st ICAAC, 2001. Abstract 1763.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/47\">",
"      Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 2008; 197:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/48\">",
"      Adams J, Patel N, Mankaryous N, et al. Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents. Ann Pharmacother 2010; 44:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/49\">",
"      Asahchop EL, Oliveira M, Wainberg MA, et al. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob Agents Chemother 2011; 55:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/50\">",
"      Tambuyzer L, Nijs S, Daems B, et al. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. J Acquir Immune Defic Syndr 2011; 58:18.",
"     </a>",
"    </li>",
"    <li>",
"     Whitcomb J, Deeks S, Huang W, et al. Reduced susceptibility to NRTI is associated with NNRTI hypersensitivity in virus from HIV-1-infected patients. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA Jan 30-Feb 2nd 2000. Abstract 234.",
"    </li>",
"    <li>",
"     Coakley E, Parkin N. Contribution of non-Thymidine Analog Nucleoside RT Inhibito Associated Mutations to Phenotypic Hypersusceptibility to Efavirenz.12th Conference on Retroviruses and Opportunistic infections. Boston, MA 22-25 February 2005. Abstract 704.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/53\">",
"      Haubrich RH, Kemper CA, Hellmann NS, et al. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS 2002; 16:F33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/54\">",
"      Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21:395.",
"     </a>",
"    </li>",
"    <li>",
"     Rinehart A. Prevalence of darunavir resistance associated mutations in samples received for routine clinical resistance testing. Fifth European HIV Drug Resistance Workshop, Casais, Portugal, March 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/56\">",
"      De Meyer S, Lathouwers E, Dierynck I, et al. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. AIDS 2009; 23:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/57\">",
"      Delaugerre C, Buyck JF, Peytavin G, et al. Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study). J Clin Virol 2010; 47:248.",
"     </a>",
"    </li>",
"    <li>",
"     Danner S, et al. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). December 16-19, 2001. Chicago IL. Abstract 1-1925.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/59\">",
"      Nijhuis M, Wensing AM, Bierman WF, et al. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V. J Infect Dis 2009; 200:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/60\">",
"      Gathe J, Cooper DA, Farthing C, et al. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis 2006; 43:1337.",
"     </a>",
"    </li>",
"    <li>",
"     Kohlbrenner VM, et al. DART 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/62\">",
"      Naeger LK, Struble KA. Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients. AIDS 2007; 21:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/63\">",
"      Schapiro JM, Scherer J, Boucher CA, et al. Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score. Antivir Ther 2010; 15:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/64\">",
"      Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/65\">",
"      Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/66\">",
"      Si-Mohamed A, Piketty C, Tisserand P, et al. Increased polymorphism in the HR-1 gp41 env gene encoding the enfuvirtide (T-20) target in HIV-1 variants harboring multiple antiretroviral drug resistance mutations in the pol gene. J Acquir Immune Defic Syndr 2007; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     Greenberg ML, Melby T, Sista P, et al. Baseline and On-treatment susceptibility to Enfuvirtide seen in TORO 1 and TORO 2 to 24 weeks. 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 10-14 February 2003. Abstract 141.",
"    </li>",
"    <li>",
"     Stawiski E. Coreceptor tropism predictions based on V3 loop sequence in antiretroviral experienced patients are specific but insensitive for detection of CXCR4-using variants. Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/69\">",
"      Su Z, Gulick RM, Krambrink A, et al. Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J Infect Dis 2009; 200:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/70\">",
"      Pugach P, Marozsan AJ, Ketas TJ, et al. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007; 361:212.",
"     </a>",
"    </li>",
"    <li>",
"     Hazuda D, et al. The 48th ICAAC/IDSA 46th Annual Meeting. October 25-28, 2008, Washington, DC. Abstract 898.",
"    </li>",
"    <li>",
"     Miller M, Danovich R, Ke Y, et al. Longitudinal analysis of HIV resistance to integrase inhibitor raltegravir: results from P005 a phase II study in treatment-experienced patients. XVII HIV drug resistance workshop June 10-14, 2008, Sitges, Spain; abstract#6.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/73\">",
"      Quercia R, Dam E, Perez-Bercoff D, Clavel F. Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. J Virol 2009; 83:10245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/74\">",
"      Hu Z, Kuritzkes DR. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J Acquir Immune Defic Syndr 2010; 55:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/75\">",
"      Goethals O, Clayton R, Van Ginderen M, et al. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 2008; 82:10366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/76\">",
"      Paar C, Palmetshofer C, Flieger K, et al. Genotypic antiretroviral resistance testing for human immunodeficiency virus type 1 integrase inhibitors by use of the TruGene sequencing system. J Clin Microbiol 2008; 46:4087.",
"     </a>",
"    </li>",
"    <li>",
"     Eron J, et al. Abstract MOAB0105, International AIDS Conference, Vienna 2010.",
"    </li>",
"    <li>",
"     file://www.retroconference.org/2011/Abstracts/42541.htm (Accessed on May 09, 2011).",
"    </li>",
"    <li>",
"     Eron J, Kumar P, Lazzarin A, et al. DTG in subjects with HIV exhibiting RAL resistance: functional monotherapy results of VIKING study cohort II. Program and abstracts of 18th Conference on Retroviruses and Opportunistic Infections; Feb 2011; Boston, USA. Paper 151LB.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/80\">",
"      Gallien S, Delaugerre C, Charreau I, et al. Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia. AIDS 2011; 25:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/26/34218/abstract/81\">",
"      Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006; 42:1608.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3772 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-11D65C23BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_26_34218=[""].join("\n");
var outline_f33_26_34218=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H52\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19101617\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF RESISTANCE TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BASIC TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19102023\">",
"      Wild-type virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19102152\">",
"      Viral fitness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19102159\">",
"      Replication capacity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19102196\">",
"      Resistance selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19102011\">",
"      Mutational patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Signature mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cross-resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hypersusceptibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Accessory mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Genetic barrier to resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2899363\">",
"      Pharmacokinetic boosting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIs)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Zidovudine and stavudine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Common resistance mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Implications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Lamivudine and emtricitabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Common resistance mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Implications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Tenofovir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Common resistance mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Implications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Abacavir and didanosine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Common resistance mutation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Implications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Multinucleoside resistance mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIs)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Common mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Implications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Hypersusceptibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      PROTEASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Cross-resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Common mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Atazanavir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15740146\">",
"      - Darunavir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15740245\">",
"      - Fosamprenavir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Indinavir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Lopinavir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15740282\">",
"      - Nelfinavir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15740260\">",
"      - Saquinavir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Tipranavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H392453\">",
"      Implications for use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      FUSION INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1263082\">",
"      Common mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H392619\">",
"      Implications for use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      CCR5 ANTAGONISTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1263089\">",
"      Tropism testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Maraviroc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H392645\">",
"      Implications for use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      INTEGRASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Raltegravir and elvitegravir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1263096\">",
"      Common mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H392771\">",
"      Implications for use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3772\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3772|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/11/16569\" title=\"figure 1\">",
"      Mutations NRTIs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/60/4039\" title=\"figure 2\">",
"      Mutations PIs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/61/37841\" title=\"figure 3\">",
"      Mutations entry inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/33/1553\" title=\"figure 4\">",
"      Mutations integr inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3772|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/17/34075\" title=\"table 1\">",
"      NRTI resistance summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/19/38204\" title=\"table 2\">",
"      Etravirine susceptibility",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/34/10794?source=related_link\">",
"      Adverse effects of antiretroviral therapy in developing countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/34/7720?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9287?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/46/3814?source=related_link\">",
"      Clinical trials of HIV drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32424?source=related_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/39/24186?source=related_link\">",
"      Factors affecting HIV progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/40/30345?source=related_link\">",
"      Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36265?source=related_link\">",
"      Modifying HIV antiretroviral therapy regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/48/4873?source=related_link\">",
"      Overview of HIV drug resistance testing assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41209?source=related_link\">",
"      Pharmacology of nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27994?source=related_link\">",
"      Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21546?source=related_link\">",
"      The global human immunodeficiency virus pandemic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_26_34219="Hypertension awareness and Rx";
var content_f33_26_34219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F82423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F82423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Trends in the awareness, treatment, and control of high blood pressure in adults in the United States",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        NHANES II 1976-1980",
"       </td>",
"       <td class=\"subtitle1\">",
"        NHANES III 1988-1991",
"       </td>",
"       <td class=\"subtitle1\">",
"        NHANES III 1991-1994",
"       </td>",
"       <td class=\"subtitle1\">",
"        NHANES 1999-2000",
"       </td>",
"       <td class=\"subtitle1\">",
"        NHANES 2007-2008",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Awareness",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        81",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        72",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Control*",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The data are for adults age 18 to 74 years of age with a systolic pressure &ge;140 mmHg and/or a diastolic pressure &ge;90 mmHg.",
"    <div class=\"footnotes\">",
"     * Control is defined as a systolic pressure below 140 mmHg and a diastolic pressure below 90 mmHg.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, JAMA 2003; 289:2560, and from US Trends in Prevalence, Awareness, Treatment, and Control of Hypertension 1988-2008, JAMA 2010; 303:2043.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_26_34219=[""].join("\n");
var outline_f33_26_34219=null;
var title_f33_26_34220="Canada Guide pulm dis kid tx";
var content_f33_26_34220=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F81028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F81028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation, continued",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pulmonary disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Recommendations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        1. Patients with the following respiratory conditions and severity are not candidates for kidney transplantation:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Requirement for home oxygen therapy (Grade C)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Uncontrolled asthma (Grade C)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Severe cor pulmonale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Severe chronic obstructive pulmonary disease (COPD)-pulmonary fibrosis or restrictive disease with any of the following parameters (Grade C):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        best forced expiratory volume in 1 s (FEV1) &lt;25% predicted value",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        PO2 room air &lt;60 mmHg with exercise desaturation, SaO2 &lt;90%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        &gt;4 lower respiratory infections in the last 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        moderate disease with evidence of progression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Patients with moderate COPD-pulmonary fibrosis or restrictive disease with any of the following parameters have a relative contraindication for kidney transplantation (Grade C):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Best FEV1 25-50% of predicted value",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        PO2 room air &lt;60-70 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Restrictive disease with exercise desaturation, SaO2 90%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. Patients should be strongly encouraged to stop smoking before kidney transplantation. Patients who continue to smoke may be eligible for kidney transplantation with full informed consent regarding their increased risk (Grade C).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4. Children with bronchopulmonary dysplasia, pulmonary hypoplasia or other significant chronic lung disease should be evaluated for transplantation in consultation with a pediatric respirologist (Grade C).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The strength of evidence supporting each recommendation was graded using the system developed by the Canadian Task Force on Preventive Health Care as follows:",
"     <br>",
"      Grade A - There is good evidence to support",
"      <br>",
"       Grade B - There is fair evidence to support",
"       <br>",
"        Grade C - The existing evidence is conflicting, but other factors may influence decision-making",
"        <br>",
"         Grade D - There is fair evidence to recommend against",
"         <br>",
"          Grade E - There is good evidence to recommend against",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Knoll, G, Cockfield, S, Blydt-Hansen, T, et al. Canadian Society of Transplantation: Consensus guidelines on eligibility for kidney transplantation. CMAJ 2005; 173:S1. Copyright &copy; 2005 CMA Media Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_26_34220=[""].join("\n");
var outline_f33_26_34220=null;
var title_f33_26_34221="CHD ECG gated SPECT";
var content_f33_26_34221=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ECG gating improves the specificity of perfusion imaging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 346px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 115 women undergoing exercise perfusion imaging, the specificity for the diagnosis of significant coronary heart disease, defined as a stenosis &gt;70 percent, with thallium-201 (TI-201) or technetium-99m (Tc-99m) sestamibi was 67 and 84 percent, respectively. Specificity was significantly improved with ECG gated SPECT using Tc-99m sestamibi (92 percent, p = 0.0004).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Taillefer, R, Depuey, EG, Udelson, JE, et al, J Am Coll Cardiol 1997; 29:69.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_26_34221=[""].join("\n");
var outline_f33_26_34221=null;
var title_f33_26_34222="Extraarticular fracture of the first metacarpal";
var content_f33_26_34222=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extraarticular fracture of the first metacarpal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 264px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This anteroposterior radiograph shows a type III fracture of the proximal 1st metacarpal with characteristic sparing of the articular surface. Significant shortening of the metacarpal is also apparent in this view.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_26_34222=[""].join("\n");
var outline_f33_26_34222=null;
var title_f33_26_34223="Pneumococcal pneumonia CXR";
var content_f33_26_34223=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pneumococcal pneumonia CXR",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    64 year old male with insulin dependent diabetes mellitus. He was admitted with bacteremic pneumococcal pneumonia. Note the left lower lobe opacity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas J Marrie, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_26_34223=[""].join("\n");
var outline_f33_26_34223=null;
